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ABSTRACT 
1,1-Bis(3’-indolyl)-1-(p-substitutedphenyl)methanes 
Induce Apoptosis and Inhibit Renal Cell Carcinoma Growth.  (August 2007) 
Melissa Dawn York, B.S., Texas A&M University 
Chair of Advisory Committee:  Dr. Stephen Safe 
Renal cell carcinoma (RCC) accounts for 85% of kidney cancer incidence in the 
US.  Since 1950 there has been a 126% increase in kidney cancer incidence in 
the US.  Thirty percent of new patients present with a localized easily treatable 
carcinoma while 30% of patients present with a high-grade metastatic 
carcinoma.  Five-year survival rates for metastatic RCC is 6-12 months 
(Lipworth et al, 2006).  Current disease treatment options  for metastasis include 
chemotherapy and radiation (8% response rate), immunotherapy (15-30% 
response rate) and newly developed angiogenesis inhibitors which are in phase 
III trials (Staehler et el, 2005).  
 
In RCC cells, it has been shown that PPARγ agonists inhibit cell proliferation, 
induce apoptosis, and induce anti-angiogenic effects in vitro.  Unlike most tumor 
types, PPARγ is downregulated in tissue samples from 47 RCC patients.  
However, in cell culture studies PPARγ expression does not correlate with 
growth inhibitory or apoptotic effects of PPARγ agonists in renal cell lines 
indicating that PPARγ independent responses may play a large role in actions 
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associated with the PPARγ agonists (Yuan et al, 2006).  1,1-Bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes containing p-trifluoromethyl, p-t-butyl and p-phenyl 
substituents activate peroxisome proliferator-activated receptor γ (PPARγ) and 
inhibit growth of ACHN and 786-0 renal cell carcinoma cell lines.  PPARγ is 
overexpressed in ACHN cells and barely detectable in 786-0 cells, and 
treatment with the t-butyl analog (DIM-C-pPhtBu) induces cell cyle inhibition.  
DIM-C-pPhtBu also induced several common PPARγ-independent proapoptotic 
responses in ACHN and 786-0 cells, including increased expression of 
nonsteroidal antiimflammatory drug-activated gene-1 (NAG-1) and endoplasmic 
reticulum stress which activates death receptor 5 and the extrinsic pathway of 
apoptosis.  In addition, DIM-C-pPhtbu (40 mg/kg/d) also inhibited tumor growth 
in an orthotopic mouse model for renal carcinogenesis, and this was 
accompanied by induction of apoptosis in renal tumors treated with DIM-C-
pPhtBu but not in tumors treated with the corn oil vehicle (control).  Thus, DIM-
C-pPhtBu and related compounds represent a novel class of mechanism-based 
drugs that have potential for treatment of renal adenocarcinoma for which there 
are currently limited options for successful chemotherapy. 
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I. INTRODUCTION 
Kidney Anatomy and Physiology 
Kidney Physiology.  The kidney has five main functions within the body, the 
regulation of body fluid osmolality and volume, electrolyte balance, the acid-base 
balance, the excretion of metabolic products and foreign substances, and the 
production and secretion of hormones.  Fluid osmolality is important for the 
function of all organs, the kidney excretes and reabsorbs solutes based on water 
and solute intake.  In the human body, the serum osmolality is maintained 
between the narrow range of 285-295 mosm/l primarily by regulation of sodium 
levels (Tareen et al., 2005).  Osmolality is controlled through the kidney by 
signals from the cardiovascular and central nervous systems.  A second 
important function of the kidney is to maintain electrolyte and metabolite 
concentrations in equilibrium despite changes in dietary intake.  Electrolytes 
controlled by kidney function include sodium, potassium, chloride, bicarbonate, 
calcium, and phosphate ions.  Metabolic intermediates excreted through the 
kidney including citrate and succinate generated through the Krebs cycle 
(Tareen et al., 2005).  Enzymes are active over a very narrow pH range and the 
lung and kidney are important for maintining pH within the 7.1-7.4 range.   
 
 
____________________ 
This thesis follows the style of Molecular Pharmacology.
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The kidney serves to excrete acid products taken in through the diet or 
synthesized in the body as metabolic byproducts.  In addition, kidneys also 
participate in regulation of the bicarbonate buffer system by selective 
reabsorption of HCO3- and production of new bicarbonate through ammonium 
production (Wagner et al., 2006).  The kidney also has specialized transport and 
filtration mechanisms to ensure that toxicants and metabolic waste products are 
excreted through the kidney while selectively retaining proteins and other 
biochemicals.  Natural waste products include urea from the metabolic 
breakdown of amino acids, uric acid generated from nucleic acid metabolism, 
and creatinine that is from muscle creatinine.  In addition to natural waste 
products, the kidney also actively eliminates many foreign substances including 
drugs and pesticides and their metabolites.  Patients with decreased renal 
function are unable to excrete these exogenous substances, thus changing the 
toxicological profile of the drug (Dekant and Vamvakas, 1996).  In addition to 
secretion, the kidney is responsible for production of several important 
hormones including calcitriol, and erythropoietin.  Renin is produced by the 
kidney to regulate blood pressure through activation of the rennin-angiotensin-
aldosterone system (Ruth and Wassner, 2006).  Calcitriol secretion is important 
for regulation of calcium reabsorption in the GI tract as well as calcium bone 
deposition (Hoenderop et al., 2005).  Patients with chronic renal disease often 
develop bone abnormalities as a result of decreased bone deposition.  
Erythropoietin exhibits anti-inflammatory activity and secretion is necessary for 
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red blood cell development in the bone marrow consequently, chronic renal 
failure patients often develop anemia and inflammation (Levin, 2006).   
 
Renal Structure and Function.  The kidney is symmetrically paired, located 
against the posterior wall of the abdomen behind the peritoneum and on either 
side of the vertebral column.  The adult human kidney weighs between 115-170 
grams and is 11 cm long, 6 cm wide and 3 cm thick.  The kidney is divided into 
two strata, the medulla at the core and the cortex at the outer surface.  
Components of the kidney include blood vessels, nephrons, lymphatics and 
nerves (Stanton and Koeppen, 2001). 
 
Twenty percent of total cardiac output of a kidney at rest is directed to the 
kidneys through the renal artery (O’Conner, 2006).  The renal artery along with 
the renal vein and the pelvis make contact with the kidney through an 
invagination in one side, subsequently the vasculature branches in the cortex 
direction into interlobar arteries, arcuate arteries, and finally into afferent 
arterioles.  Blood flow through the afferent arterioles is dispersed into the 
glomerular capillary network, and then combined again to form efferent arterioles 
(Fig. 1).  The control of the afferent and efferent arterioles through vasodilatation 
and vasoconstriction control the resulting pressure of blood flow and filtration 
rate (Campese and Park, 2007).   
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Fig. 1.  Low magnification scanning electron micrography of renal cardiovascular casts. 
(af) afferent arteriole (ef) efferent arteriole (ArA) arcuate artery (AI) interlobular artery 
(Kimura et al., 1990). 
 
 
 
Efferent arterioles branch into the vasa recta to supply blood to the outer and 
inner medulla.  The efferent arterioles then divide to form the peritubular 
capillary bed to allow reabsorbtion of filtrate.  The renal arteriole system runs 
opposed to the renal venous system that forms progressively the interlobular 
vein, arcuate vein, interlobar vein and finally the renal vein (Stanton and 
Koeppen, 2001).   
 
Renal Filtration.  Sixty percent of the adult body weight is water, two thirds 
existing as intracellular fluid and one third as extracellular fluid.  Extracellular 
fluid consists of 75% interstitial fluid and 25% plasma (Verbalis, 2003).  The 
downhill movement of sodium ions across the gradient is the main driving force 
for fluid and chemical reabsorption in the kidney.  In bodily fluid, sodium is the 
major cation while chloride and bicarbonate are the major anions and the 
balance and composition of major ions is controlled by the kidneys filtration 
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system.  In order to maintain the stable ion concentrations in the blood, the 
kidney filters a three times the volume of the total body water every day (Ruth 
and Wassner, 2006). 
 
Each human kidney consists of more than 1.2 million nephrons dispersed 
throughout the cortex and medulla.  Nephrons are composed of cells 
constructed into a hollow tube of a single cell layer.  Nephron structure consists 
of a renal corpuscle attached to a proximal tubule, which leads to a hairpin turn, 
called Henle’s loop.  The upturn in Henle’s loop leads to the distal tubule and 
finally to the collecting duct system (Fig. 2).  Each segment of a nephron is 
uniquely differentiated to play a unique role in filtration of substrate (Stanton and 
Koeppen, 2003). 
 
 
Fig. 2.  Nephron structure.  Filtrate flows into the glomerular apparatus through the 
afferent arteriole and then passes into the proximal tubule and then into the loop of 
Henle and the distal tubule.  Final filtrate collection occurs in the collecting ducts.   
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Glomerular Apparatus.  The renal corpuscle that ultra concentrates molecules 
from the blood into the tubular space, is located in the cortex and is comprised of 
glomerular capillaries and the Bowman’s capsule.  Epithelial cells called 
podocytes cover the glomerular capillaries forming the filtration barrier (Kanwar, 
1984).  In addition to the capillaries and podocytes, mesangial cells are the 
active immune responsive elements and are similar to monocytes.  The last 
important feature of the renal corpuscle is the juxtaglomerular apparatus, which 
is in contact with the afferent arteriole that actively controls renal blood flow. 
 
To ultra concentrate substrates, hydrostatic pressure from the afferent arteriole 
in the glomerular capillaries forces water and filtrates to collect in the Bowman’s 
space.  The glomerular filtration barrier has a net negative charge resulting in 
reduced filtration of anionic proteins.  Proteins and ions <20 angstroms pass 
easily through the negatively charged filtration barrier.  However, proteins 
between 20-45 angstroms are selectively filtered based upon their cationic 
charge.  Any molecule larger than 45 angstroms will not pass through the 
filtration barrier (Brenner, 1976; Kanwar, 1984).   
 
The glomerular apparatus and associated juxtaglomerular apparatus are 
responsible for regulation of blood pressure via the renin, angiotensin system. 
Kidney regulation of blood pressure occurs during activation of the sympathetic 
nervous system or when blood pressure is low and is illustrated in Figure 1.3.  In 
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these situations, renin is produced in specialized cells that line the afferent 
arteriole and catalyzes the cleavage of circulating angiotensinogen to give 
angiotensin I.  Angiotensin I is subsequently cleaved by angiotensin to give the 
final product, angiotensin II (Ang II).  Ang II binds to G-protein coupled receptors 
to cause vasoconstriction (Campese and Park, 2007).  In contrast to the release 
of renin, the glomerular apparatus is also affected by the release of NO from the 
proximal tubule and Henle’s loop.  NO has actions opposite to angiotensin II and 
acts as a vasodilator to reduce renal vascular resistance.  In response to high 
blood pressure, NO is produced by the enzyme endothelial nitric oxide synthase 
(eNOS) in renal tubular epithelial cells (Fig. 3).  NO expression reduces sodium 
reabsorption by inhibiting Na-K-2Cl transporters that move Na from the tubule 
lumen into the blood (Herrera et al., 2006; Marin and Sessa, 2007). 
 
The following nephron structures ensure that molecules that are either beneficial 
or of low availability are reabsorbed into the system.  For example, although 
approximatly 8 grams of calcium ion are concentrated daily by the glomerulli, 
only 0.16 grams are excreted in the urine (Hoenderop et al., 2005).   
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Fig. 3.  Protective and restorative responses to volume loss.  Renin is released from the 
kidney in response to a drop in blood pressure, resulting in activated angiotensin I that 
is converted to catalytically active angiotensin II that acts as a vasoconstrictor.  If blood 
pressure increases eNOS expression is induced resulting in increased production of 
nitric oxide that inhibits the action of Na-K-2Cl transporters leading to vasodilation. 
 
 
Proximal Tubule.  Once waste products and urine have been concentrated in 
the renal corpuscle, they flow into the proximal tubule.  Proximal tubule cells 
have differential apical and basolateral a surface and the surface area of the 
apical, reabsorption side is increased though brush border surfaces (Kinne, 
1975).  Sodium potassium pumps maintain differential concentrations of major 
ions in the extracellular and intracellular fluids.  For example in the extracellular 
fluid, sodium ion is actively maintained at 145 mEq/L while the intracellular fluid 
contains only 12 mEq/L of this ion. 
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In the proximal tubule, 67% of the filtered water is passively reabsorbed along 
with soluble sodium, chloride, and potassium ions.  The proximal tubules are 
responsible for the reabsorption of approximately 80% of filtered HCO3- by the 
action of two proton transporters, the Na+/H+ exchanger NHE-3 and H+-ATPase 
(Nakamura, 2004).  In proximal tubules, the passive, downhill movement of 
sodium across its concentration gradient through these transporters is coupled 
to the passive import of glucose, calcium as well as other molecules (Suki, 
1979).  Once inside the cell, glucose and other molecules move downhill from 
the basolateral membrane into the blood.  In addition to the movement of 
solutes, charged metabolic proteins and nephrotoxic molecules such as 
cadmium bound to metallothionein can be endocytosed and broken down (or 
released) by lysosomes in the proximal tubule cells (Dekant and Vamvakas, 
1996).   
 
Large or highly charged particles often cannot pass through the filtration barrier 
because they bind strongly to plasma proteins such as albumin (Robertson and 
Rankin, 2006). In addition to the reabsorption of important electrolytes, proximal 
tubule cells are also important for the secretion of large organic anions and 
cations through nonspecific transporter systems.  The activity and concentration 
of these transporters can determine xenobiotic-induced nephrotoxicity by 
controlling the excretion of charged nephrotoxic drugs and environmental 
toxicants.  Organic cations that are excreted include many alkaloids, positively 
 10 
 
charged heterocyclic compounds from dietary sources, and recreational or 
therapeutic drugs including nicotine and cisplatin (Wright, 2005).  The multidrug 
resistance transporter multidrug resistance transporter (MDR1) controls the 
efflux of both anionic glutathione A-conjugates, unmodified anionic 
chemotherapeutic agents as well as bulky, polyvalent organic cations (Miller, 
1995; Cole et al., 1992).  Smaller, positively charged monovalent compounds 
such as tetraethylammonium (TEA) move across the electrical potential gradient 
from the blood to the basolateral membrane by the passive action of organic 
cation transport (OCT) proteins (Inui et al., 2000).  In contrast, organic ions are 
secreted uphill by the actions of organic anion transport (OAT) proteins.  Organic 
anions that are excreted include cyclic nucleotides, prostaglandins, uric acid, 
and drugs such as Β-lactam antibiotics, methotrexate and nonsteroidal anti-
inflammatory drugs (NSAIDs; Apiwattanakul et al., 1999; Uwai et al., 1998).  
Regulation of electrolyte reabsorption in the proximal tubule is controlled by 
aldosterone secretion.  An increase in aldosterone results in increased sodium 
channel synthesis, particularly the epithelial sodium channel (ENaC), thus 
increasing sodium reabsorption into the blood (Ruth and Wassner, 2006). 
 
Henle’s Loop.  Once through the proximal tubules and into the medulla, the 
substrate flows through Henle’s loop through several consecutive structures 
termed the descending thin limb, the ascending thin limb and then a thick 
ascending limb. Unlike the highly differentiated proximal tubule cells, the cells 
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composing the thin descending and ascending limbs of Henle’s loop are poorly 
differentiated and contain few mitochondria.  The thin ascending limb is 
impermeable to water and is highly invaginated with high concentrations of 
mitochondria. In the thick ascending limb of Henle’s loop, 25% of the filtered 
potassium, calcium and bicarbonate are returned to the blood supply (Stanton 
and Koeppen, 2001). 
 
One important function of Henle’s loop is the activation and regulation of calcium 
levels in the blood through vitamin D activation.  Vitamin D3 is synthesized by 
the action of UVB radiation (290-325 nm) on 7-dehydrocholesterol present in the 
plasma membrane of epidermal keratinocytes and dermal fibroblasts (Holick, 
2003).  Once generated, vitamin D3 binds to vitamin D binding protein that 
transports the structure to the liver for further processing by hydroxylation to 
generate 25-hydroxyvitamin D3 (25(OH)D) (Fig. 4). 
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Fig. 4. Vitamin D synthesis and blood calcium regulation.  The final step of vitamin D 
synthesis occurs in the kidney and leads to increased RANKL activity and calcium 
channel espression in the gut resulting in increased calcium blood levels.   Modified 
from Holik et al., 2003. 
 
 
 
Hydroxylated vitamin D is transported into the tubules and oxidized by 
cytochrome p450s specific to the kidney to generate the final product, 1,25 
dihydroxyvitamin D3 (Nykjaer et al., 1999; Takeyama et al., 1997).  The final 
product moves back into the blood where its primary action is upon the vitamin D 
receptor (VDR) that enhances uptake of calcium in the diet and facilitates the 
release of calcium stored in bones.  To increase calcium uptake the VDR 
mediates increased expression of epithelial calcium channel proteins and 
thereby enhanced calcium absorption in the intestines (Holick, 2004).  In 
contrast, activation of VDR in osteoblasts increases expression of receptor 
activator of nuclear factor (NK)-ΚB (RANK) ligand (RANKL), which promotes 
maturation of preosteoclasts to osteoclasts.  Mature osteoclasts release HCl and 
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collagenases to destroy the bone matrix thus releasing calcium and phosphorus 
into circulation (Khosla, 2001).   
 
Collecting Ducts.  After leaving the thick ascending limb, substrates flow from a 
distal tube to the cortex, and into a cortical collecting duct. The collecting duct is 
a blend of two cell types, namely principal cells with low differentiation and 
intercalated cells that contain a high density of mitochondria.  The cortical 
collecting duct is connected to the inner medullary collecting duct that contains 
poorly differentiated cells.  The collecting duct is important for regulation of 
bodily fluid osmolality.  An increase in body osmolality by as little as 1-4% can 
cause thirst by the release of arginine vasopressin, formally known as 
antidiuretic hormone (ADH) (Robertson, 1983; Thompson et al., 1986).  ADH is 
synthesized in the hypothalamus and stored in neurosecretory granules in the 
pituitary until needed (Robertson, 1995).  ADH in the kidney increases water 
retention through interaction with AVP V2 receptors in the kidney.  Activation of 
argenine vasopressin (AVP) V2 receptors increases water permeability of the 
collecting duct by insertion of aquaporin-2 water channels (Knepper and Inoue, 
1997).  The final result is a decrease in urine volume and a reciprocal increase 
in urine osmolality.  In contrast, when the blood becomes hypotonic to the 
intercellular fluid through salt loss, the kidneys respond by secretion of renin in 
the glomerular apparatus leading to the release of aldosterone.  Aldosterone 
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acts on the cortical collecting duct to reabsorb both salt and water returning the 
blood to proper osmotic levels (Ruth and Wassner 2006). 
 
Chronic and Acute Kidney Disease 
Patients can present with two general types of kidney disease, chronic renal 
disease and acute renal failure.  The end stage for both diseases is end stage 
renal disease (ESRD) at which point all functions of the kidney are lost and the 
patient must consider dialysis or transplantation for survival. 
 
Acute renal disease or acute renal failure (ARF) is the sudden and reversible 
loss of kidney function.  In general, nephrotoxic substances of environmental 
origin or sudden changes in renal perfusion can cause ARF.  Interestingly, 7.2% 
of hospitalized patients develop ARF, the major causes being decreased renal 
perfusion 39% (congestive heart failure, cardiac arrest, and volume contraction), 
nephrotoxin administration 16%, contrast administration 11%, and major surgery 
9% (Nash et al., 2002).    
 
In the year 2000, it was estimated that 9.6% percent of Americans, 
corresponding to 19 million people had some form of chronic kidney disease 
(CKD) (Coresh et al., 2005).  Unlike acute kidney disease, the nephrotic damage 
in chronic kidney disease is irreversible.  CKD is strongly linked to 
cardiovascular disease and diabetes in the American population and is the 
 15 
 
leading cause of morbidity and mortality in CKD patients (Sarnak and Levey, 
2000).   
 
Interestingly, cardiovascular disease and CKD may be synergistic and even 
causal in their action.  In some cases, mild undiagnosed CKD may be a 
precipitating factor in the development of cardiovascular disease due to mild 
kidney function dysregulation leading to volume overload, anemia, and 
hypertension.  In contrast, cardiovascular disease may cause a blood volume or 
flow dysregulation producing chronic kidney disease (Jaradat and Molitoris, 
2002).  For example, diseased glomerular cells produce higher levels of renin 
compared to normal cells leading to vasoconstriction through increased levels of 
Ang II directly leading to hypertension.  In addition to vasoconstriction, Ang II 
plays many roles in inflammation and increases levels of many inflammatory 
agents including IL-6, TNF-α, NK-ΚB (Suzuki et al., 2003). 
 
Renal Dysfunction.  The development of chronic or acute kidney disease is 
linked to the dysregulation of body fluid osmolality, electrolyte maintenance, acid 
base regulation, and/or protein excretion. 
 
The regulation of osmolality is important for cell and organ function.  Changes in 
the osmolality of the blood or extracellular fluid results in the flow of into and out 
of the cell.  Depending on the osmotic gradient, these shifts can cause 
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significant swelling and contraction of organelles.  For example, uncontrolled 
diabetes mellitus leads to hyperosmolality by solute movement against the 
increased cellular concentration of glucose (Ruth and Wassner, 2006).  
Hyperosmotic blood causes water to flow from cells into the extracellular fluid 
and makes the cells lose volume.  In the brain, membranous tethering allows 
only 15% shrinkage, leading to tearing of membrane-bound blood vessels and 
development of intracranial hemorrhages precipitating permanent neurological 
damage (Trachtman, 1991).   
 
Hyperosmotic conditions can be generated by kidney dysregulation when 
congenital defects occur within the ADH receptor pathway.  ADH insensitivity 
can occur within the defects in the AVP V2 (X-linked recessive pattern of 
inheritance) receptor or the aquaporin-2 gene (autosomal recessive pattern of 
inheritance) (Fujiwara et al., 1995).  Related decreases in AVP V2 activation lead 
to decreased aquaporin-2 expression thus significantly reducing the body’s 
ability to reabsorb water in the collecting duct (Verbalis, 2003). 
 
In contrast, vomiting and diarrhea can lead to blood which is hypotonic to the cell 
resulting in water movement from the blood into cells which induces swelling.  In 
the brain, cells cannot swell due to the presence of the bony skull and hypotonic 
blood can lead to intracellular cerebral edema, seizures and death (Trachtman, 
1991).  Interactions with the kidney can be a causal factor in the production of 
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hypoosmotic blood, in the syndrome of inappropriate ADH secretion (SIADH) 
where ADH secretion is upregulated causing the formation of high 
concentrations of aquaporin in the collecting duct.  SIADH can be caused by 
drugs, infections, and is a common complication in lung carcinoma (Verbalis, 
2003). 
 
One of the major functions of the kidney is the regulation of calcium levels in the 
blood stream and dysregulation of this system can cause hyperkalemia (too 
much calcium) and hypocalcemia (too little calcium) leading to cardiac 
arrhythmia and altered myocardial contractility in acute cases (Commandeur and 
Vermeulen, 1990).  As discussed above, in chronic kidney disease many 
patients have low circulating levels of activated vitamin D (1,25(OH)2D) and are 
unable to absorb calcium in the intestines leading to a net reduction in blood 
serum calcium levels (Christiansen et al., 1981; Takamoto et al., 1985).  To 
compensate, PTH is released to enhance osteoclast activity in the bone matrix 
(Portale et al., 1984).  In growing children, this condition can cause rickets due 
to normal circulating calcium but low circulating phosphate (Holick, 2004).  In 
adult CKD patients, increased PTH causes destruction of the mineral and bone 
matrix of the skeleton causing osteoporosis. In addition, many CKD patients live 
in chronic pain caused by swelling in the inflamed bone matrix.  To compensate, 
many doctors prescribe vitamin D supplements to ease the pain and stop the 
loss of bone mass (Malabanan et al., 1998).  
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Dysregulation of calcium levels by kidney disease can also lead to formation of 
atherosclerotic plaques.  Atherosclerotic disease is defined as the fibrofatty 
plaque formation with late calcification leading to stiffening of arteries, or a 
circumferential lesion with calcification earlier in the course of the disease 
(Starry, 2000).  Vascular smooth muscle cells differentiate from the same 
mesenchymal stem cells as osteoblasts.  In CKD patients, high levels of 
circulating calcium generated as a result PTH derived bone loss, can cause 
vascular smooth muscle cells to transdifferentiate and take on osteoblastic 
character.  In vitro calcium administration causes differentiated vascular smooth 
muscle cells to produce osteopontin, alkaline phosphatase and osteocalcin thus 
hypothetically causing mineralization of the vascular structure (Parhami et al., 
1996).  
 
The disruption of the acid base balance through renal tubular acidosis or 
metabolic alkalosis can be created or potentiated by many common disorders.  
Renal tubular acidosis is caused by disruption of the kidney’s ability to regulate 
acid-base concentrations; this disease is seen in many hereditary and acquired 
conditions.  For example a mutation in the gene encoding the Na+/HCO3- 
cotransporter (SLC4A4) disrupts the ability of the proximal tubules to reabsorb 
bicarbonate resulting in excessive urinary bicarbonate wastage and severe 
metabolic acidosis (Alper, 2002; Dinour et al., 2004).  Decreased bicarbonate in 
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the blood leads to an increase in circulating acid byproducts, resulting in 
cerebral calcification, osteoporosis and glaucoma leading to blindness (Wagner 
et al., 2005).   
 
Excess protein in the urine is a high predictor for the development of CKD.  
Proteinurea is always caused by structural defects in the glomerular apparatus.  
Glomerular apparatus damage can occur due to nephron damage caused by 
autoantigen generation or due to hereditary problems such as nephritic 
syndrome and Alport's syndrome. 
 
Membranous nephropathy is the generation of glomerular subepithelial immune-
complex deposits resulting in decreased urinary protein excretion. It is estimated 
that 30-40% of patients reach end stage renal disease within 5-15 years. The 
mechanism of immune complex generation in the disease is unknown but 
membranous nephropathy has been linked to toxicity generated by mercury, 
gold, and penicillamine (Nangaku and Couser, 2005).  Current hypotheses 
describe either the release of antigens from damaged proximal tubules 
provoking an autoimmune response or the clumping of insoluble immune 
complexes in the glomerular apparatus filtration barrier (Edgington et al., 1968; 
Nagi et al 1971).  In contrast, nephrotic syndrome is an increase in glomerular 
membrane permeability leading to net loss of essential protein from the 
bloodstream.  An example is congenital nephritic syndrome of the Finnish type 
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(NPHS1) that is caused by mutation in the NPHS1 gene that encodes for 
nephrin which is a major component of the glomerular filtration apparatus.  In the 
absence of nephrin, filtration components such as the slit diaphragm and foot 
processes are missing (Fig. 5).  Porteinuria develops during the fetal period 
leading to nephritic syndrome and death soon after birth (Kestila et al., 1998).  
There is no medical cure for NPHS1 and kidney transplantation is performed at 
the age of 1-2 years (Holmberg et al., 1995). 
 
 
Fig. 5.  Electron microscope picture of glomerular capillary wall. (A) Normal structure 
shows regular foot processes enclosing the glomerular basement membrane.  (B) 
NPHS1 kidney, podocytes processes and slit diaphragm are missing (Jalanko et al., 
2001). 
 
 
Another common example of glomerular damage resulting in porteinuria is 
Alport’s syndrome which is defined as the presence of blood in the urine linked 
to a defect in collagen matrix in the glomerular apparatus.  Eighty-five percent of 
patients presenting with familial Alport’s Syndrome have an X-linked mutation in 
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type IV collagen (gene COL4A5) (Lemmink et al., 1997).  In the absence of this 
collagen subtype, the glomerular basement membrane is exposed to proteases 
and oxidants and the glomerular membrane becomes thick, splitting, and 
deteriorating.  This results in lack of size differential filtration (Kalluri et al., 1997).  
In this disease, blood in the urine can lead to inflammation of glomerular 
capillaries resulting in hypertension and renal failure (Dische et al., 1985).   
Cancer – An Introduction 
Statistics provided by the National Cancer Institute Surveillance Epidemiology 
and End Results (SEER) indicate that in the United States in the year 2007, 
1,444,920 will be diagnosed with and 559,650 people will die of cancer in 2007 
(Mariotto et al., 2007).  For all cancers, the median age at death was 73 years of 
age.  Between their 50th and 70th birthdays, 21.26% of men and 15.56% of 
women will develop cancer at some site.  Although total cancer mortality has 
been declining at a rate of 2.1% between the years of 2002-2004, the overall five 
year relative survival rate is only 64.9% (Mariotto et al., 2007).  
 
Tumor Development Model.  Cancer development is a multi-step process with 
an estimated four to seven rate limiting events (Renan, 1993).  In general, the 
stages are categorized as initiation, promotion and progression (Hursting et al., 
1999).     
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Initiation.  Initiation involves mutations of critical DNA elements that allow 
selective growth advantage over normal cells and can occur due to DNA adduct 
formation by endogenous and exogenous carcinogens.  Endogenous 
carcinogens include many types of reactive oxygen species (ROS) that are 
normal byproducts of oxidative metabolism and UV radiation.   
 
Exogenous toxins are ubiquitous and can cause carcinogenesis by covalent 
adduct formation with DNA bases (Weinstein, 1988).  Xenobiotic metabolizing 
enzymes are present in many organs of the body including the liver and kidney. 
The liver is the main site of xenobiotic metabolism via phase I enzymes called 
cytochrome p450s (CYPs).  CYP enzymes account for 70-80% of all xenobiotic 
metabolizing enzymes and are primarily located in the endoplasmic reticulum 
(ER), mitochondria, and plasma membrane (Evans and Relling, 1999).  CYP 
acts as a hemoethiolate monooxygenase in which the conserved peptide motif 
Phe-X(6-9)-Cys-X-Gly (X denotes any amino acid) binds octahedral iron and 
transfers one atom of atmospheric oxygen to a substrate (Bachschmid et al., 
2005).  CYPs catalyze the oxidation or epoxidation of C-H and carbon-carbon 
double bonds to give more hydrophilic metabolites (Anders, 1980).  Phase II 
enzymes conjugate reactive electrophilic species with polar intermediates for 
secretion in the bile.  It is estimated that only 25% of all carcinogenic compounds 
create adducts in their natural form, the other 75% must first undergo metabolic 
activation by CYP oxidative enzymes to generate reactive intermediates (Nebert 
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and Dalton, 2006).  Metabolic activation of procarcinogens creates an 
electrophilic compound capable of binding to nucleophilic sites.  Selectivity of 
binding targets is based on the relative “hardness” of the electrophile and 
nucleophile, thus hard electrophiles will selectively bind hard nucleophiles (Table 
1; Commandeur and Vermeulen, 1990). 
 
 
Table 1:  Reactivity of electrophiles and nucleophiles.  In order of increasing hardness 
(Commandeur and Vermeulen, 1990). 
Electrophiles
aldehydes
polarized double bonds
epoxides
strained ring lactones
alkyl sulfates
alkyl halides
aryl carbonium ions
benzylic carbonium ions
nitrenium ions
alkyl carbonium ions
Target Nucleophiles
thiol groups (cisteinyl residues in protiens and glutathione)
sulfur atoms (methionyl residues)
primary and secondary amino groups in protien
amino groups and purine bases in DNA and RNA
oxygens of purines and pyrimidines in DNA and RNA
phosphate oxygen of RNA and DNA
 
 
 
 
The kidney also contains significant CYP450 levels, however, most p450 activity 
in the kidney is involved in synthesis of endogenous sterols and hormones such 
as vitamin D (Dekant and Vamvakas, 1996).  Nevertheless, select compounds 
can cause nephrotoxicity and tumorigenesis by metabolic activation in the 
kidney.  For example, high doses of acetaminophen result in renal necrosis by 
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two mechanisms involving either direct oxidation catalyzed by CYPs or 
deacetylation followed by CYP-dependent oxidation.  Direct CYP450 oxidation 
results in the reactive intermediate N-acetylbenzoquinonimine, an intermediate 
with little renal toxicity.  However, primary deacetylation creates ρ-aminophenol 
which is oxidized to the final electrophilic product benzoquinoneamine that is 
capable of creating adducts to nucelophilic species (Fig. 6; Commandeur and 
Vermeulen, 1990). 
 
 
Fig. 6.  Bioactivation of acetaminophen in the proximal renal tubule.  Reactive 
intermediates capable of covalent binding to macromolecules are underlined by dashed 
lines (Commandeur and Vermeulen, 1990).   
 
 
CYP450-dependent metabolic activation can also cause DNA adduct formation 
at distant sites and cigarette smoke is a good example of this type of activity.  
Sixty-five percent of all cancers have been linked to carcinogen exposure due to 
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diet and the environment (Koide et al., 1999).  US cancer deaths attributable to 
cigarette smoking are as high as 30% (Doll and Peto, 1981).  Skin exposure to 
cigarette smoke condensate can cause nearly 50,000 stable DNA adducts for 
every 24 hours of exposure (Melendez-Colon et al., 1999).  The most 
carcinogenic compound identified in smoke is a polycyclic aromatic hydrocarbon 
(PAH) called benzo(a)pyrene (BaP).  BaP is metabolically activated by 
cytochrome p450 and epoxide hydrolase in cells to generate BaP-7,8-
dihydrodiol-9,10-epoxide (BPDE). 
 
Electrophilic diol epoxides such as BPDE form covalent adducts at the N2 of 
guanine.  Upon DNA replication, bulky adducts at guanine N2 create a unique 
GT transversion in the p53 gene (Ruggeri et al., 1993).  Consequently, in 
smokers p53 mutations are most often found in areas associated with GT 
transversions (Fig. 7; Rubin, 2002).   
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Fig. 7.  p53 point mutations caused by mutagens. (A) All cancers (B) lung cancer in 
nonsmokers (C) lung cancer in smokers (D) lung cancer in nonsmokers exposed to 
smoky coal emissions (Weinberg et al., 2007). 
 
 
Proximal tubule cells have low concentrations of activating CYPs, however, 
kidney cells have the highest levels of β-lyase activity and this is an alternative 
bioactivation pathway (Boogard et al., 1989; Commandeur et al., 1989).  The 
phase II enzyme GST catalyzes the conjugation of electrophilic compounds and  
glutathione for subsequent secretion in the bile (Anders, 2004).  In the proximal 
tubule γ-glutamyltransferase (GGT) catalyzes a salvage pathway resulting in 
hydrolysis of glutathione S-conjugates to cysteine S-conjugates that are 
removed from the plasma by active transporters in the kidney (Lash and Anders, 
1989).  Once concentrated in the nephron, bioactivation to cytotoxic metabolites 
is catalyzed by pyridoxal-phosphate-dependent β-lyase and bioactivation of 
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haloalkanes can also occur after addition of glutathione follwed by β-lyase-
dependent-bioactivation (Cooper et al., 2002).   
 
Glutathione dependent activation is implicated in the tumorgenicity of select 
dihalomethanes such as dichloromethane.  Dichloromethane is used as a 
solvent, degreaser, paint remover, and the manufacture of photographic film.  In 
the liver CYP-dependent biotransformation generates carbon monoxide as the 
final product, however, in the kidney GST-dependent conjugation is catalyzed by 
theta-class GST giving S-(chloromethyl)glutathione and  formaldehyde as 
products (Kubic and Anders, 1978; Ahmed and Anders, 1978; Reitz et al., 1989).  
Historically, formaldehyde has been implicated in the tumorgenicity of 
dichloromethane, however, it was demonstrated by Wheeler et al. (2002) that 
glutathione conjugates of dihalomethanes are genotoxic in bacterial assays 
while formaldehyde generates no mutations.  Downstream metabolic activation 
can occur in β-lyase-catalyzed β-elimination reactions of 1,1-dichloalkene 
derived cysteine S-conjugates.  For example, bioactivation of S-(1,2-
dichlorovinyl)-L-cysteine yields pyruvate, ammonia and 1,2 
dichloroethenethiolate that can lose chloride to give chlorothioketone or 
tautomerize to give the chlorothioacetyl chloride (Cooper et al., 2005).  
Thioketenes are highly reactive and chlorothioketone can give DNA adducts to 
cytosine in organic solvents (Volkel and Dekant, 1998).  Evidence for thioketene 
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formation in the reaction was obtained by Fourier-transform ion cyclotron 
resonance mass spectrometry (Fig. 8; Zhang et al., 1995). 
 
 
Fig. 8.  Biotransformation of S-(1,2-dichlorovinyl)-L-cysteine by β-lyase-catalyzed β-
elimination (Anders, 2004). 
 
 
Not all initiating events result in tumorigenesis due to the action of specialized 
DNA repair enzymes.  Base excision repair enzymes repair alkylated bases by 
removal of the damaged base and replacement with the corresponding Watson-
Crick complement.  Methyltransferases repair methylation at the O6 or O4 of 
guanine or thymine respectively.  Long strands of mismatched bases (27-29 
nucleotides) can be generated by DNA adducts or UV light photodimers and 
these are repaired by nucleotide excision repair enzymes (Hursting et al., 1999). 
 
Promotion.  Once initiation has occurred, selective pressure by various 
promoters allow clonal expansion of initiated cells.  Promoting agents 
themselves are not carcinogenic but provide selective pressure through the 
expression of genes for hyperproliferation, tissue remodeling, and inflammation 
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(Hursting et al., 1999).  In effect, tumor promoters increase proliferation at the 
expense of regulatory apoptosis. 
 
The concentration of BPDE in cigarettes has been estimated to be only 2% of 
the concentration necessary for development of cancer based on results of 
studies with BaP alone.  However, cigarettes enhance inflammation and cell 
proliferation through many pathways.  First, the repeated cytotoxic insults 
offered by the caustic chemical milieu can result in rapid and widespread cell 
death mediated by necrosis and apoptosis.  High selective pressure can lead to 
the selective proliferation of resistant cells that are insensitive to immune system 
surveillance or necrotic signals (Rubin, 2002).  Second, promoters can act 
directly on epithelial cells to favor cancer cell growth by stimulating proliferation, 
altering gene expression, generating free radicals, and inhibiting cellular 
communication and apoptotic signals (Wright et al, 1994).  Cigarette smoke 
contains high concentrations of the tumor promoter catechol, a phenolic 
compound with two adjacent hydroxyl groups (Hecht et al., 1981).  Other 
chemical promoters in cigarette smoke include other phenols, non-aromatic 
hydrocarbons (decane, undecane, tetradecane) and non-carcinogenic aromatic 
hydrocarbons such as (B(e)P), benzo(g,h,i)perylene and long chain alcohols and 
acids (lauryl alcohol, stearic acid) as well as cocarcinogens with action weaker 
than BaP (Van Duuren and Goldschmidt, 1976).  Cigarretes also contain high 
concentrations of the promoter nicotine and the average pack-per-day smoker 
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absorbs 20-40 mg of nicotine each day resulting in plasma concentrations of 23-
35 ng/ml by the afternoon (Zhang et al, 2006).  Nicotine in the plasma interacts 
with nicotinic acetylcholine receptors (nAChRs) found in many endothelial and 
vascular smooth muscle cell types (Macklin et al., 1998).  Zhang et al. (2006) 
demonstrated that pretreatment of human lung cancer cells with 100 µM nicotine 
for 6 hours followed by treatment with 100 µM menadione, an apoptosis inducer, 
significantly reduced the percentage of cells undergoing late stage apoptosis 
from 52% to 30% (Fig. 9)   
 
 
Fig. 9.  Nicotine prevents apoptosis induced by methadione in human lung cancer cells.  
Early apoptotic cells exhibit Annexin V+/propidium iodide (PI)- and late apoptotic cells 
exhibit Annexin V+/PI+ signatures in flow cytometric analysis.   
 
 
 
It has been suggested that nicotine inhibits apoptosis induction by several 
mechanisms, including activation of the mitogen activated protein kinase 
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(MAPK) and protein kinase C (PKC) pathways as well as overexpression of anti-
apoptotic Bcl-2 proteins (Zhang et al, 2006).   
 
Progression.  Progression is a series of genetic changes that result in clonal 
expansion in the absence of promoters (Pilot, 1989).  In Hanahan’s Hallmarks of 
Cancer, six essential steps are defined in tumorigenesis: self-sufficiency in 
growth signals, insensitivity to growth-inhibitory (antigrowth) signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, 
and tissue invasion and metastasis (Hanahan and Weinberg, 2000).  In kidney 
tumor development, mutations of the “gate keeper” gene von-Hippel-Lindau 
(VHL) can contribute too many of these traits, making it an essential target 
during progression (Kopper and Timar, 2006).   
 
Self Sufficiency in Growth Signals.  Nontransfromed cells require positive 
interactions with growth signals for proliferation whereas cancer cells lose 
dependence on outside signals.  For example, normal propogation of cells in 
culture requires addition of mitogenic factors and matrix proteins for integrin 
adhesion; in contrast tumor cells can grow in the absence of matrix proteins and 
at low serum levels (Hanahan and Weinberg, 2000). Growth signals can be 
transduced through interactions with members of the diffusible growth factors, 
extracellular matrix proteins, and cell-to-cell adhesion molecules.  Cancer cells 
often engage in two types of signaling; normal heterotypic signaling in which 
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cells generate growth factors that interact with neighboring cells and autocrine 
signaling an unusual adaptation allowing cancer cells to provide their own 
signaling molecules in a feedback loop.  Examples of heterotypic signaling in 
tumorigenesis are growth stimulatory factors generated by immune cells in 
response to inflammation (Cordon-Cardo and Prives, 1999).  In kidney cancer, 
the loss of the gatekeeper VHL gene creates overexpression of both EGFR and 
its growth stimulatory ligand, TNFα that generate an autocrine feedback loop.  
Smith et al. (2005) demonstrated growth of tumor tissue in mice could be 
completely inhibited by silecing this autocrine loop by inhibition of EGFR by 
inhibitory RNA (Fig. 10; Smith et al., 2005). 
 
 
Fig. 10.  Silencing of EGFR suppresses VHL -/- RCC tumor formation.  Average tumor 
mass 9-weeks post injection.  In all cases they failed to detect any tumor formation 
following shRNA injection into EGFR expressing VHL -/- RCC cells (Smith et al., 2005). 
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The EGFR autocrine loop is important in many cancer types including stomach, 
brain and breast cancer (Yarden and Ulrich, 1988).  Many cancers receive 
growth signals independent of ligands through the use of mutated or 
overexpressed growth factor receptors.  In addition to the regulation of growth 
factor receptors, most cancer cells also gain the ability to switch cell-cell 
adhesion molecules to favor proliferation.   
 
Integrins are highly conserved cell surface receptors composed of two subunits, 
α and β, and each αβ combination has a unique ligand specificity for different 
extracellular matrix (ECM) components.  ECM activation is transduced through 
adaptor proteins to many receptors including protein tyrosine kinases such as 
focal adhesion kinase (FAK), Src family kinases and Integrin-linked kinases.  As 
an example, FAK signaling is activated by many αβ combinations and results in 
FAK autophosphorylation to create a binding site for Src homology 2 (SH2) 
domains of Src (Schaller et al., 1994).  Signal transduction occurs through 
activation of phosphoinositide-3 kinase (PI3K) which then phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2) at the 3’ position of the inositol ring 
to generate PIP3.  Phosphoinositide-dependent kinase 1 (PDK1) is recruited to 
the plasma membrane by PIP3 action through its plekstrin homology domain 
where it phosphorylates and activates AKT (Dillon et al., 2007).  AKT 
translocates to the nucleus where its phosphorylation activity is implicated in the 
production of positive growth signals by mammalian target of rapamycin (mTOR) 
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among others (Mita et al., 2003).  mTOR is overexpressed in many kidney 
cancers and is implicated in the induction of VHL targets (Staehler et al., 2005).  
Activity of PI3K is regulated by phosphatase and tensin homolog deleted on 
chromosome 10 (PTEN), which removes 3’ phosphate of PIP3 to abrogate the 
signal (Dillon et al., 2007).  Consequently, the PTEN gene is often 
downregulated in RCC (Steahler et al., 2005).  In addition to PI3K activation, Src 
phosphorylates FAK a second time resulting in an exposed binding site for the 
adaptor proteins Grb2 and Ras guanosine 5’-triphosphate exchange factor 
mSOS (Schlaepfer et al., 1994).  Ras is a membrane associated GTP-ase that 
cycles between GTP-bound active and GDP-bound inactive states through the 
activating action of guanine-nucleotide exchange factors (Giehl, 2005).  
Activated Ras recruits the serine/threonine kinase Raf to the plasma membrane 
for activation and subsequent phosphorylation of MEK-1 and 2 also known as 
mitogen-avtivated protein kinase (MAPK) that itself phosphorylates ERK 1 and 
2.  Phosphorylated ERK translocates to the nucleus and interacts with 
transcription factors to promote cell proliferation (Giehl, 2005).  Ras is also 
located downstream of many autocrine growth factor receptors including EGFR, 
vascular endothelial growth factor receptor (VEGFR), and platelet-derived 
growth factor receptor (PDGFR; Fig. 11; Staehler et al., 2005).  
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Fig. 11.  Self sufficiency in growth signals.  Integrin signaling through FAK kinase 
results in signal transduction through the PI3K/AKT and Raf/MEK/ERK signaling 
pathways.  Ras can also be activated through receptor binding of growth factors. 
 
 
 
The Raf/MEK/ERK signaling pathway is constitutively activated in kidney cancer 
cell lines.  Mechanisms of constitutive activation of Ras specific to renal 
carcinoma are unknown but 25% of all tumors express a mutated form of Ras 
that is constitutively activated (Medema and Bos, 1993). 
 
Insensitivity to Growth Inhibitory Signals.  The second hallmark for cancer is 
insensitivity to growth inhibitory signals that generate quiescence or 
differentiation.  Cancer cells proliferating in culture can be forced to exit the 
proliferative cycle into a quiescent state termed G0 (Hanahan and Weinberg,  
2000).  An example of this action in renal cell carcinoma is insensitivity to 
transforming growth factor-β (TGF-β) signaling.  TGF-β is a potent cytokine that 
interacts with 3 receptors, Type I, II and III (TBR-1,2 and 3) and activates 
mediator Smad proteins that inhibit proliferation, promote cellular differentiation 
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and regulate interactions with the ECM (Moustakas et al., 2001).  Surprisingly, 
many studies of human renal cell carcinoma (RCC) demonstrate that RCC cells 
overexpress TGF-β and patients have high serum levels of the growth inhibitory 
cytokine (Cardillo et al., 2001; Hegele et al., 2003). In contrast, overexpression 
of TGF-β in normal cells has been implicated in development of chronic renal 
disease resulting in renal fibrosis and apoptosis (Bottinger and Bitzer, 2002).  It 
has been hypothesized that TGF-β overexpression generates 
immunosuppressive effects and provides the insensitive tumor with a favorable 
growth environment (Hegele et al., 2003).  Copland et al. (2003) demonstrated 
that in order to evade TGF-β-dependent growth inhibition, RCC cells 
sequentially lose TBR 3 and 2 expression correlating with localized and 
metastatic progression respectively (Fig. 12).  Interestingly, in RCC cells 
transfection with TBR 2 and 3 rescue the growth inhibitory phenotype (Copland 
et al., 2003). 
 
 
Fig. 12.  Rescue of TGF-β growth inhibition by overexpression of TBR 2 and TBR 3 
(R2, R3) in UMRC3 RCC cells (Copland et al., 2003). 
 37 
 
 
 
Many human tumors develop strategies to evade cell growth inhibition by TGF-β.  
For example, hereditary nopolyposis colorectal carcinoma produces loss-of-
function mutations in TBR2 and 85% of all colon carcinoma cells have complete 
loss of TBR2 (Akhurst and Derynck, 2001; Markowitz et al., 1995).   
 
Evading Apoptosis.  Classically, there are two recognized mechanisms of cell 
death, necrosis, and apoptosis.  Necrosis is generated by environmental 
perturbations, severe hypoxia/ischemia, temperature extremes, and mechanical 
trauma (Farber and Mofty, 1975).  Generally, necrosis is regarded as being an 
unplanned event that results in regional inflammation.  In contrast, apoptosis or 
programmed cell death is a highly conserved and tightly regulated event 
involved in regulated cell death during development, immune surveillance, and 
by many anti-cancer drugs.  Apoptosis is defined by morphological 
characteristics incuding; cell shrinkage, membrane blebbing, nuclear chromatin 
condensation, and fragmentation resulting in the production of a tight ball of 
membrane bound fragments exposed for phagocytosis by phagocytes 
(macrophages and dendritic cells).  Many different pathways regulate apoptotic 
activity including activation of death receptors, endoplasmic reticulum stress and 
mitochondrial pertubations (Vermeulen et al., 2005).   
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Death receptor induced (extrinsic) apoptosis is coordinated by the action of 
membrane bound receptors that are activated by extracellular signals.  The 
death receptor family includes Fas (Apo-1, CD95), TNF-receptor-1 (TNF-R1), 
death receptor 3 (DR3 or TFN-receptor related apoptosis-mediating protein 
(TRAMP) or APO-3), TNF-related apoptosis inducing ligand receptor-1 (TRAIL-
R1 or DR4), TRAIL-R2 (DR5 or Apo-2) and DR6 (Ashkenazi and Dixit, 1998).  
For example, the Fas receptor has a death domain (DD) that interacts with 
adaptor protein’s Fas-associated death domain protein (FADD) upon Fas ligand 
binding to form a death receptor-induced signaling complex (DISC) (Nagata, 
1997).  FADD in turn recruits caspase 8 through its death effector domain to 
activate the caspase cascade. 
 
Caspases are enzymes that are expressed as inactive proenzymes and 
activated by proteolytic and active caspases recognize and hydrolyze 
tetrapeptide sequences at an Asp residue (Nicholson and Thornberry, 1997).  
Targets of caspase activity include poly-(ADP)-ribose polymerase (PARP) used 
for DNA repair and inhibitor of caspase-activated DNAse (ICAD) that inhibits 
CAD or DNA fragmentation factor (DFF) (Duriez and Shah, 1997; Sakahira et 
al., 1998).  Upon ICAD cleavage, DFF translocates to the nucleus and catalyzes 
nucleosomal DNA cleavage to generate oligonucleosomal DNA fragments (Liu 
et al., 1997).  In addition, caspase cleavage of the cytoskeleton proteins fodrin 
and actin result in cytoskeletal disorganization (Mashima et al., 1995). 
 39 
 
 
In mitochondrial-dependent apoptosis (intrinsic), regulation of the balance of pro-
apoptotic (Bax, Bak) and anti-apoptotic (Bcl-2, Bcl-XI) bcl-2 protein family 
members leads to opening of the permeability transition pore (PTP) in the 
mitochondrial membrane (Burlacu, 2003).  The PTP is composed of two 
proteins, the adenine translocator (ANT) at the inner membrane and the voltage-
dependent anion channel (VDAC) at the outer membrane as well as accessory 
proteins that regulate the release of cytochrome c into the cytosol.  Once 
released, cytochrome c interacts with apoptotic protease activating factor 1 
(Apaf-1) that can bind and activate procaspase 9 to generate the mitochondrial 
DISC (or apoptosome) that activates the caspase cascade (Vermeulen et al., 
2005).  Mitochondrial-dependent apoptosis can be activated by many stimuli, for 
example p53 is stabilized in the presence of DNA damage resulting in 
cytochrome c release and apoptosis (Hanahan and Weinberg, 2000). 
 
Tumors use a number of different mechanisms to avoid apoptosis.  For example, 
more than 50% of cancers have a loss-of-function mutation in the p53 gene 
(Harris, 1996).  Mechanisms of evasion of apoptosis in renal cell carcinoma 
have only recently been elucidated.  Sejima et al. ( 2003) reported that RCC 
tissue samples had significantly reduced Fas protein and mRNA expression 
compared to normal tissue.  Interestingly, similar to TGF-β, Fas ligand (FasL) 
expression is increased in RCC cancer tissue compared to normal tissue, a 
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feature shared with hepatocellular carcinoma, melanoma, and colon 
adenocarcinomas.  It has been suggested that overexpression of FasL induces 
apoptosis in tumor infiltrating lymphocytes thus protecting the cells from the 
immune system (Strand et al., 1996).  In addition to the reduction in Fas 
receptors, RCC cell lines are also characterized by heavy methylation on the 
APAF-1 gene thus allowing evasion of both the extrinsic and intrinsic apoptotic 
pathways (Christoph et al., 2006).  Apoptosis evasion techniques used in RCC 
are illustrated in Figure 13. 
 
 
Fig. 13.   Apoptosis evasion techniques found in RCC tissue samples.  Death receptor 
mediated apoptosis is inhibited by decreased expression of Fas ligand on the cell 
surface.  Mitochondrial-dependent pathway of apoptosis is inhibited by methylation of 
APAF-1.  Decreased expression is marked by the red cross-through symbol. 
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Limitless Replicative Potential.  In the 1960’s Leonard Hayflick demonstrated 
that isolated fibroblasts had finite replicative potential correlating with a certain 
number of cellular divisions.  As the cells reached this allowable number, they 
ceased to proliferate and entered a phase termed senescence.  Morphologically, 
senescent cells are metabolically active and characterized by a flat, extended 
shape with no proliferative activity.  These observations led to the hypothesis 
that cells are subject to the actions of an internal clock that tracks the number of 
cell divisions and stops this process after a predetermined number of cell 
divisions (Hayfilck, 1965).  In the 1970’s, Watson and Olovnikov proposed a 
possible mechanism for the internal clock namely, the end replication problem, 
in which linear chromosomes are unable to replicate the extreme 3’ ends of 
chromosomes (Olovnikov, 1973, Watson, 1972).  It is now known that 
senescence is triggered by the exposure and interference of the structural 
integrity of the telomere nucleoprotein (Shay and Wright, 2005).  The 3’ end of 
every normal chromosome is capped by a telomere nucleoprotein that contains 
single and double stranded DNA in a higher ordered structure in which the 
overhanging, single tail of the G-rich strand binds to complementary upstream 
telomere sequences creating a displacement loop known as the T-loop (Griffith 
et al., 1999).  Loss of T-loop structure can be induced in vitro by the 
overexpression of a telomere nucleoprotein termed TRF2 and this results in 
DNA damage and downstream activation of p53 (Karlseder et al., 2002).  
Consequently, Shay et al. (1991) demonstrated that in human cells, induction of 
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senescence could be bypassed by the loss of only p53 (DNA damage signaling 
protein) and Rb (replication suppressive proteins).   
 
Cells that bypass senescence continue to replicate until the telomeres are 
completely degraded and cannot protect exposed chromosome ends from DNA 
regulatory mechanisms that detect and repair strand breaks.  At this point cells 
enter the crisis phase characterized by end-to-end chromosomal fusions, 
anaphase bridges (chromosomes pulled in opposite directions by centromeres), 
and apoptotic cell death (Shay and Wright, 2005).  It was observed that 1 in 
every 107 human cells will survive and exhibit no telomere shortening due to the 
induction of full-length telomerase reverse transcriptase (hTERT) enzyme or the 
activation of a telomere maintenance system termed alternative lengthening of 
telomeres (ALT; Fig. 14; Stewart and Weinberg, 2006).  hTERT catalyses a 
reverse transcriptase reaction and acts on a telomerase RNA template to add  a 
TTAGGG repeat to lengthen and stabilize the telomere.  Mechanistically, ALT is 
thought to proceed through homologous recombination, a theory strengthened 
by the finding that the addition of a unique DNA sequence in the subtelomeric 
region of a chromosome will result in its subsequent redistribution to all 
telomeres in the cell (Dunham et al., 2004).  
 
Research on renal cell carcinoma has demonstrated genetic alterations that 
bypass senescence and the crisis point.  Roe et al. (2006) demonstrated that 
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p53 signal for DNA damage is stabilized by the “RCC gatekeeper” tumor 
suppressor protein, VHL.  Specifically, p53 binds to pVHL to block Mdm2 
mediated ubiquitination, nuclear export, and subsequent proteasomal 
degradation of p53.  Thus, when VHL is lost p53 is destabilized and unable to 
transmit apoptotic signals to the mitochondria.   
 
 
Fig. 14.  Telomere hypothesis.  Telomere length (y axis) is gradually lost during cell 
division (x axis), leading to p53 and Rb dependent growth arrest called senescence.  
Inactivation of p53 and Rb allows further cell division but does not abrogate telomere 
shortening.  Telomeres erode until a crisis point is reached at which the DNA ends are 
no longer protected resulting in apoptosis.  Some clones will emerge with stable 
telomere lengths by the actions of telomerase or ALT (Stewart and Weinberg, 2006).   
 
 
The Rb protein controls progression through the cell cycle and is found at 
unaltered levels in RCC tissue, however, tumor progression correlates with 
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increasing Rb deactivation through phosphorylation (Hedberg et al., 2004).  To 
bypass the crisis point, it was demonstrated that 80% of RCC tissues express 
full length and functional hTERT whereas, 71% of normal tissues express an 
alternatively spliced hTERT with nonfunctional or dominant negative 
characteristics (Fan et al., 2005). 
 
Sustained Angiogenesis.  In solid tumors, oxygen and nutrients can passively 
diffuse only 100 µm from a capillary blood vessel, thus allowing only a finite 
tumor size (Hanahan and Weinberg, 2000).  In order to progress, tumors must 
develop the ability to recruit and sustain angiogenic growth.  A balance of 
soluble or membrane bound, pro and apoptotic factors regulate angiogenesis.  
Proapoptotic soluble factors include vascular endothelial growth factor (VEGF) 
and acidic and basic fibroblast growth factors (FGF1/2) that bind transmembrane 
kinase receptors presented by vascular cells for directional recruitment (Presta 
et al., 2005).  An example of an antiangiogenic soluble factor is thrombospondin-
1 that binds Src-like CD36 (Bull et al., 1994).  Membrane bound proteins that 
regulate angiogenesis include the integrins.  Research has shown that 
angiogenesis can be suppressed by inhibition of particular integrins expressed 
only on membranes of growing vasculature (Giancotti and Ruoslahti, 1999).  
RCC is known for its high level of vascularization, a characteristic that will be 
discussed in the next section. 
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Tumor Invasion and Metastasis.  Metastasis is the capacity of cancer cells to 
escape a primary tumor and colonize other areas in the body.  Ninety percent of 
all cancer deaths are directly linked to metastasis (Sporn, 1996).  Steps 
associated with metastasis include, escape from the primary tumor, 
translocation of tumor cells across extracellular matrix barriers, and colonization 
of secondary tumors (Woodhouse et al., 1997).   
 
The first step in metastasis is the escape of cells from the primary tumor through 
the vascular or lymph systems (intravasation) and subsequent cellular arrest in 
capillary beds of metastatic sites.  For intravasation, a tumor cell must lose 
adhesive junctions connecting it to the ECM and neighboring cells at the primary 
tumor site.  Intercellular junctions use desmosomes, gap junctions, and 
adherens junctions to mediate epithelial cell adhesion.  Cadherins are the main 
component of the adherens junction and are often lost during cancer 
progression (Esteban et al., 2006).  Once in the vasculature, three mechanisms 
have been proposed for tumor selection of metastatic targets and these include, 
selective growth, selective adhesion, and selective chemotaxis.  The selective 
growth hypothesis states that cancer cells can invade (extravasate) into every 
site equally but that growth is favored in some sites over others.  Selective 
adhesion proponents theorize that tumor cells select targets by the same 
mechanisms as white blood cells that selectively attach blood vessel walls by 
interactions of integrins, selectin and their integrins.  Selective chemotaxis is the 
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term used for the expression of certain cytokines by cancer cells and 
complementary receptors on metastasis sites (Woodhouse et al., 1997).  
 
Extravasation of the tumor cell into the new growth site requires the coordinated 
activities of ECM attachment and proteolysis proteins and occurs in only 0.05% 
of all circulating tumor cells (Liotta et al., 1974).  Invasive mechanisms are not 
unique to tumor cells and in fact, tumors use the same techniques used in 
angiogenesis, morphogenesis, and trophoblast implantation (Folkman, 1971; 
Talhouk et al., 1992; Lola and Graham, 1990).  Invasion mechanics involve the 
protrusion of a cylindrical psuedopod that expresses activated proteinases that 
lyse impeding ECM followed by adhesion at the leading edge and movement of 
the cell forward through detachment at the rear (Woodhouse et al., 1997).  
Proteolysis is carried out by a family of proteins termed the matrix 
metalloproteinases that catalyze the degradation of ECM components 
(Deryugina and Quigley, 2006).  At the new site, tumor cells must take 
advantage of local expression of growth stimulatory cytokines.  For example, 
Yoneda et al. compared the sensitivity of original tumor cells and bone 
metastatic tumor cells to insulin-like growth factor (IGF) that is expressed at high 
levels in the bone and found that only secondary site tumors were sensitive to 
IGF-dependent promotion (Yoneda et al., 2001). 
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Kidney cancer has high metastatic potential with the main sites being the bone 
and the lung.  In RCC, loss of the tumor suppressor protein VHL results in 
decreased expression of E-cadherin and increased expression of membrane 
type-1 matrix metalloproteinase and this is a deadly combination (Estaban et al., 
2006; Petrella and Brinckerhoff, 2006). 
 
Stem Cell Theory of Tumorigenesis.  Recently, the classical theory of tumor 
initiation, promotion, and progression has been contested by an alternate theory 
described as the stem cell pathway for carcinogenesis (Gudjonsson and 
Magnusson, 2005).  There are three groups of stem cells: embryonic (progenitor 
of all cells in the body), germinal (produce egg and sperm) and somatic stem 
cells (tissue renewal) (Sell, 2004).  Evidence for the somatic stem cell type is 
evident in tissue with rapid cell turnover such as skin, colon, and blood.  
Characteristics of somatic stem cells include self-renewal through asymmetric 
cell division generating differentiated progeny with a long life span (Sell, 2004).  
The principal difference between the classical and stem cell models of 
carcinogenesis is that instead of normal differentiated cells undergoing 
mutations that give them stem cell characteristics, somatic stem cells are 
mutated and become independent of inhibitory regulation, but continue to 
generate mutant partially differentiated cells.  Figure 15 provides an illustrated 
comparison between three-step carcinogenesis and stem cell carcinogenesis. 
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Fig. 15.  Models of tumorigenesis.  (A) Three-step carcinogenesis, normal differentiated 
cells undergo initiation at a DNA element that allows for selective growth advantage.  
Promotion allows selective clonal expansion and progression allows expansion in the 
absence of the promoter, final progressive targets are stem cell like in nature (B). Stem 
cell carcinogenesis, stem cells are initiated and form cancer cells with complete 
differential heterogeneity.  Cells with stem cell like characteristics are represented by 
circles, differentiated cells are represented by angular shapes.  Stars represent 
mutations in tumor suppressor genes or oncogenes that give cells selective growth 
advantage. 
 
 
If this model proves correct, modern therapies that have been developed for 
treating differentiated cells may not affect critical stem cells.  Thus, new 
therapies must target the affected stem cell populations to promote 
differentiation and maturation.  Breast cancer is a good illustration of the stem 
cell theory.  Breast cancer stem cells are hypothesized to be located in the 
luminal epithelial compartment that is singularly important for cell transformation 
(Gudjonsson et al., 2002; Sainsbury et al., 2000).  It has been observed that 
there is an exponential increase in breast cancer incidence with increasing age.  
It is argued that the long life span of stem cells would permit accumulation of 
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mutations over the course of a life time compared to the relatively short life span 
of differentiated cells.  Candidate stem cells expressing CD44 in the absence of 
CD24 (CD44+/CD24-) isolated from breast tumors are 10-50X more tumorgenic 
as the surrounding partially differentiated cells.  Interestingly, as few as 100 
CD44+/CD24- cells were capable of forming tumors that presented the same 
phenotypic heterogeneity as the primary tumor (Gudjonsson and Magnusson, 
2005). 
 
In summary, tumorigenesis is initiated by changes to DNA that create a mutated 
cell with selective growth advantages.  Promotion creates positive selective 
pressures that allow the tumorgenic cell to grow at a higher rate than 
surrounding cells.  Progression then changes DNA expression and allows cells 
undergoing progression promoter-independent growth.  After progression, a 
non-diferentiated tumor cell emerges and this cell is capable of self-renewal and 
long life.  The stem cell carcinogenesis theory allows for initiation and 
progression to occur at the level of the stem cell, thus producing differentiated 
tumor cells. 
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Kidney Cancer 
Epidemiology.  In 2006, 38,890 people will be diagnosed with kidney cancer 
and 2,840 will die of this disease in the United States (Jemal et al., 2006).  Some 
argue that kidney cancer mortality statistics are underestimated due to the fact 
that few RCC patients die of tumor metastasis but instead die of related 
complications affecting the heart and body homeostasis.  Kidney cancer has 
classically been divided into 3 large categories: renal cell carcinoma (RCC), 
renal pelvis cancer, and rare malignancies.  RCC is classified as 
adenocarcinoma that grows from primary tubule epithelium while renal pelvis 
cancers are transitional cell carcinomas.  RCC accounts for 85% of kidney 
cancer incidence in the U.S. and is the subject of our studies (Lipworth et al., 
2006). Three different varieties of RCC are observed: clear cell RCC (75%), type 
1 papillary RCC (5%), and chromophobe RCC and oncocyoma (1%; Lipworth et 
al., 2006).  All cell lines used in our study are clear cell renal carcinoma cells.  
Since 1950, there has been a 126% increase in kidney cancer incidences in the 
U.S. (Volpe and Jewett, 2005).  In the past, renal cell carcinoma has occurred 
twice as often in men as in women with an average age of diagnosis at 60 years.  
However, recently rates have been increasing more rapidly for females than 
males.  Some argue that the increase in cancer incidence is a direct result of 
improved imaging and diagnostic equipment but increased incidence rates have 
been reported for all stages of RCC (Fig. 16; Lipworth et al., 2006). 
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Fig. 16.  Trends in 2000 United States standard age adjusted incidence of renal cell 
cancer by race and sex in 1973 to 2002 based on SEER data (Lipworth et al., 2006). 
 
 
Fifteen to forty-eight percent of kidney cancers are discovered incidentally during 
diagnosis for unrelated abdominal pain (Tsui et al., 2000).  Kidney cancer does 
not have any distinctive symptoms, and the classic triad of RCC symptoms, 
“flank pain, haematuria and a palpable mass”, are rarely seen the in clinic and 
indicate high grade, metastatic tumors.  Symptoms of early stage RCC include a 
grouping of variable symptoms such that RCC has taken the nickname of 
“internists cancer”.  Symptoms include hypertension, anemia, weight loss, fever, 
elevated alkaline phosphatase, hypercalcemia, and hepatic necrosis (Wotkowicz 
and Libertino, 2007).  RCC prognosis and staging is determined using definitions 
in the 2002 TNM Classification based on clinical manifestations (Table 2).   
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Table 2.  The TNM staging system. 
Primary Tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor 7 cm or less in greatest dimension, limited to the kidney
T1a Tumor 4 cm or less in greatest dimension, limited to the kidney
T1b
T2 Tumor more than 4 cm in greatest dimension, limiten to the kidney
T3
T3a
T3b
T3c
T4 Tumor invades beyond Gerota's fascia
Regional Lymph Nodes (N)
NX Regional lymph node cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single regional lympph node
N2 Metastasis in more than one regional lymph node
Distant Metastasis (M)
MX Distant metastasis cannot be assessed
M0 No distant metastasis
M1 Distant metastasis
Stage Grouping
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T1 N1 M0
T2 N1 M0
T3 N0 M0
T3 N1 M0
T3a N0 M0
T3a N1 M0
T3b N0 M0
T3b N1 M0
T3c N0 M0
T3c N1 M0
Stage IV T4 N0 M0
T4 N1 M0
Any T N2 M0
Any T Any N M1
Tumor grossly extends into the renal cava above diaphragm or 
invades the wall of the vena cava
Tumor more than 4 cm but not more than 7 cm in greatest dimension, 
limited to the kidney
Tumor extends into major veins or invades adrenal gland or 
perinephroc tissue but not beyond Gerota's fascia
Tumor directly invades adrenal gland or perirenal and/or renal sinus 
fat but not beyond Gerota's fascia
Tumor grossly extends into the renal vein or its segmental (muscle 
containing) branches, or vena cava below the diaphragm
 
 
Risk Factors.  Rates for kidney cancer vary by more than 10-fold between 
regions/countries suggesting that environmental factors may be important for 
this cancer. Highest incidence rates for RCC are observed in Western and 
Eastern European countries while lowest rates are observed in Asia and Africa 
(Lipworth et al., 2006).  Factors implicated in this disease include cigarette 
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smoking, obesity, hypertension, analgesic usage, diet, alcohol, hormonal and 
reproductive factors, occupation, and kidney disease.   
 
Estimates of RCC incidence due to cigarette smoking are as high as 20-30% in 
men and 10-20% in women (McLaughlin et al., 1995).  A recent meta-analysis of 
24 trials, found a relative risk of RCC development for smokers at 1.54 for males 
and 1.22 for females.  The relationship between RCC and smoking is 
complicated by the finding that current smokers with RCC have an increased 
risk of death compared to non-smokers with RCC (hazard ratio 1.7) (Sweeney 
and Farrow, 2000).  Heavy smokers (21+ cigarettes daily) have a relative risk of 
2.03 in males and 1.54 in females.  RCC risk decreases substantially (15-30%) 
with within 10-15 years after smoking cessation in men and women (Hunt et al., 
2005). 
 
Obesity can be considered as both a cancer initiator by increased lipid 
peroxidation leading to endogenous ROS generation and cancer promotion by 
hypertension and increased glomerular filtration resulting in inflammation.  Forty 
percent of RCC incidence every year is directly linked to obesity.  Recent 
analysis indicated that a relative risk for RCC of 1.07/U increase in body mass 
index (Bergstrom et al., 2001).  RCC will often result in the dysregulation of body 
osmolality and volume control augmenting the effects of obesity and increasing 
hypertension.  Hydrochlorothiazide and furosemide are commonly used diuretics 
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prescribed for treatment of hypertension and interestingly both have been linked 
with renal tubule cancers in rats (McLaughlin and Lipworth, 2000).  However, 
parallel increases in risk for human patients have not been documented.  
Patients undergoing long-term dialysis for end stage renal disease have an 
increased risk of RCC compared to the general population (Lipworth et al., 
2006). 
 
Since the introduction of phenacetin, analgesics have long been postulated to 
cause kidney cancer.  Phenacetin caused cancers of the renal pelvis but was 
withdrawn from the market for 25 years ago.  Today, although the analgesics 
aspirin, acetaminophen as well as other NSAIDS have been investigated, no 
correlation between their use and RCC has been found (McCredie et al., 1995).  
Large studies have found no increased risk associated with increased exposure 
to these drugs. 
 
A study by Hemminki and Xinjan (2002) found that second generation 
immigrants to Sweden had kidney cancer risk profiles more closely linked to the 
host country than their ancestral origin implicating dietary and environmental 
factors in RCC tumorigenesis (Hemminki and Xinjun, 2002).  Consequently, in 
2005 a Swedish study found high consumption of fruits and vegetables and 
alcohol consumption to be protective against RCC (Rashidkhani et al., 2005).  
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Although high protein diets are a known risk factor for kidney disease, no 
correlation has been found for RCC incidence (Lipworth et al., 2006).  
 
Environmental toxicants implicated in RCC include asbestos, gasoline, and 
trichloroethylene (TCE).  Epidemiology studies on the role of environmental 
factors are problematic due to the numerous confounders including smoking and 
obesity.  Studies on asbestos have not conclusively linked exposure to RCC 
risk; three studies have found a correlation while one meta-analysis has found 
no increased risk (Lipworth et al., 2006).  Gasoline involvement in RCC has 
been suspected since the early 1980s when exposed male rats developed renal 
cancer.  However, epidemiological studies have found no correlation between 
gasoline exposure and RCC risk.  A possible explanation for the discrepancy 
was reported in 1993 with the discovery of male rat specific expression of α2-
microglobulin.  Androgen control leads to the synthesis of α2-microglobulin in 
the liver of male rats and α2-microglobulin binds to chemicals in gasoline that 
make it resistant to protease hydrolysis.  Unable to degrade α2-microglobulin, 
the cell accumulates high concentrations in lysosomes of the proximal tubule 
leading to lysosomal disruption and cell necrosis resulting in increased 
compensatory cell proliferation.  Interestingly, a similar protein was extracted 
from the urine of human males with renal disease but it does not have the 
capability to bind to gasoline extracts and is found at very low concentrations.  In 
summary, the renal carcinogenicity of gasoline in humans is limited by the 
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absence of the α2-microglobulin protein (Dekant and Vamvakas, 1996).  TCE 
has been implicated in RCC carcinogenesis in both animal models and human 
studies.  Brauch et al. (2004) found a significant (8 year) difference between age 
at diagnosis for TCE exposed and non-exposed RCC patients (Fig. 17).  
However, the correlation between RCC and TCE exposure has not been 
confirmed and will be the subject of future studies (Lipworth et al., 2006). 
 
  
Fig. 17.  Age distribution of RCC diagnosis in occupationally TCE-exposed (black bars) 
and non-exposed patients (white bars) (Brauch et al., 2004). 
 
 
Presentation.  Thirty percent of all RCC patients present with localized 
noninvasive disease that is easily controlled by radical nephrectomy or tumor 
enucleation (Bichler and Wechsel, 1999).  However, another 30% of all RCC 
patients seem to present with localized disease, but then progress into 
metastatic disease within 5 years of diagnosis (Sabo et al., 1997).  Incidental 
 57 
 
diagnosis of patients with invasive metastatic disease occurs in forty percent of 
all RCC diagnosis.  RCC metastasis is very difficult to treat and the median 
survival time for patients presenting with metastatic disease is 6-12 months 
(Staehler et al., 2005).  Common sites of metastasis include the lung and lymph 
nodes with bone and brain as secondary sites of invasion (Tomita, 2006).  In 
RCC, high native concentrations of multi-drug resistance protein as well high 
activity of regional glutathione systems confer resistance to both chemotherapy 
and radiation (Gurova et al., 2004).  In addition, RCC is known for having high 
intratumoral heterogeneity with both diploid and aneuploid cells within the same 
tumor (Bichler and Wechsel, 1999).   
 
Treatment Options.  FDA approved treatment options have changed little since 
the 1980s and localized RCC is best treated with surgical methods that remove 
the primary tumor.  Classical surgical methods include radical nephrectomy with 
regional lymphadenectomy and ipsilateral adrenalectomy to decrease chances 
of unresecteed metastasis (Wotcowicz and Libertino, 2007).  New nephron-
sparing techniques are gaining popularity due to increased risk of kidney 
disease in RCC patients.  Nephron sparing techniques include laparascopic 
partial nephrectomy, cyroablation, and energy-ablative therapy (Wotkowicz and 
Libertino, 2007).  Surgery of primary or secondary tumors has little therapeutic 
value except to decrease pain, malaise, and hypercalcemia (Staehler et al., 
2005).  As late as 2005, immune therapy was the only treatment for metastasis. 
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Immune targeted therapies developed in the early 1990s allowed partial control 
of metastasis for the first time.  It had been observed that 6-7% of placebo 
treated patients undergo spontaneous regression after immune challenging 
nephrectomy, inflammation, or infectious insults (Young, 1998).  Immunoediting 
is the regulation and control of tumor cells by the immune system (Dunn et al., 
2002).  A characteristic of RCC is the compromise of the immune system.  For 
example, RCC tumor infiltration by dendritic cells is decreased compared to 
normal cells.  Second, T cell reactions to tumor associated antigens are inhibited 
so that instead of the release of effector cytokines (interleukin-2 (IL-2), 
interferon-α (IFNα)) that would promote apoptosis, compromised T cells instead 
secrete immunosuppressive cytokines (Michael and Pandha, 2003).  New 
immune therapies attempt to stimulate the natural immune system by the 
introduction of exogenous IL-2 and IFN-α. 
 
IFN-α is a glycoprotein secreted in response to viral infections and foreign 
antigens that promotes expression of major histocompatibility complex (MHC) I 
molecules on the surface of the molecule.  MHC class I antigen presenting cells 
interact with T-cell receptor for T-cell activation and target cell lysis (Fig. 18; 
Dembic et al., 1986; Clevers et al., 1988).  Ten to fifteen percent of RCC 
patients treated with IFN-α have some response, 2% present with complete 
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regression while most have only a delay of 6-7 months in progression 
(McDermott and Rini, 2007).   
 
 
Fig. 18.  Immunotherapy against RCC using IFN-α.  IFN-α therapy promotes 
expression of MHC-1 of cell surface of RCC tumor cells making it a target for cytotoxic 
T cells. 
 
  
IL-2 glycoprotein is produced in response to infection and is necessary for 
regular lymphocyte function and growth.  Specific functions include the 
discrimination between self and foreign antigens.  IL-2 stimulates natural killer 
cells to secrete IFN-α, granulocyte-macrophage colony stimulating factor (GM-
CSF) and tumor necrosis factor α (TNF-α) that activates macrophages and 
causes maturation of antigen presenting cells (APC) for increased T cell activity 
and subsequent apoptosis (Fig. 19; Bleumer et al., 2003).   
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Fig. 19.  Immunotherapy against RCC using IL-2. IL-1 stimulates natural killer cells to 
secrete TNF-α that activates macrophages, increases MHC-1 expression on surface of 
tumor cells and causes maturation of APC cells resulting in increased T-cell activity. 
 
 
The response of RCC patients to IL-2 is correlated with the expression of the 
carbonic anhydrase IX (CAIX) antigen presentation on cellular surfaces.  CAIX is 
overexpressed in >90% of RCC cases due to ubiquitous loss of the von Hippel-
Lindau allele (Kim et al., 2004; McDermott and Rini, 2007).  CAIX expression is 
particularly high in primary or low stage tumors but decreases with advancing 
stage (Bui et al., 2003).  Response rates for IL-2 therapy in metastatic disease 
vary from 3-39% depending on the differentiation characteristics of the tumor 
cells.  For example, good predictive features include morphological features 
allowing for >50% alveolar and no granular or papillary features.  Conversely, 
only 3% of patients with bad predictive features (>50% granular or papillary 
features) will respond to IL-2 therapy (McDermott and Rini, 2007). 
 
Von-Hippel Lindau.  New treatment options using molecular targets specific to 
RCC for antitumor activity have been reported.  The Von-Hippel Lindau (VHL) 
 61 
 
allele is considered the gate-keeper of RCC.  In mice, reintroduction of VHL will 
completely suppress RCC formation in VHL-/- cell line (Virtanen and Lehto, 
2004).  It is estimated that 1 in 35000 people in the US are affected by 
inheritance of a mutation at one VHL allele in an autosomal dominant pattern of 
inheritance (Vira et al., 2007).  The VHL gene is found at chromosome 3p25-26 
and expression patterns are highest in the kidney, eye and lung (Mukhopadhyay 
et al., 1997).  Loss of VHL presents as a silent disease whose symptoms first 
appear as tumors of the CNS, kidney, adrenal gland, pancreas and retina.  Sixty 
percent of VHL patients develop RCC making it the primary cause of death 
(Mukhopadhyay et al., 1997; Staehler et al., 2005).  VHL patients that develop 
RCC present with numerous solid and cystic lesions and one estimate gave an 
average of 1100 cysts and 600 clear cell neoplasms per kidney (Vira et al., 
2007). 
 
Eighty-four to ninety-eight percent of sporadic (noninherited) RCC has loss of 
heterozygocity at the VHL allele.  Forty percent of patients have mutations in the 
remaining allele while another 10% have silencing methylation at the VHL allele 
(Rini and Rathmell, 2007).  The product of the VHL gene (pVHL) forms a 
complex that ubiquitinates protein kinase C, decreases expression of matrix 
metalloproteases (MMPs), and increases expression of MMP inhibitors (Kopper 
and TImar, 2006).  In addition to MMP regulation, one primary target is hypoxia 
inducible factor (HIF) that regulates hypoxia-responsive genes.   
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In normoxic conditions, HIF is expressed at low levels in the cytoplasm.  Without 
hypoxic stimulus, HIF is hydroxylated on conserved prolyl and arginyl residues 
by oxygen dependent prolyl and arginyl hydroxylases.  pVHL is synthesized and 
forms a multiprotein complex (VEC) along with elongins B and C, cullin 2, and 
rbx1 at the hydroxylated α domain of the HIF molecule (Leung and Ohh, 2002).  
In hypoxic conditions, HIF is not hydroxylated and is not bound by pVHL for 
targeted degradation.  HIFα binds to its constitutively expressed partner, HIFβ to 
initiate transcription of genes containing the DNA sequence 5’-RCGTG-3’ that 
regulate angiogenic, metabolic, and proliferative factors (Fig. 20; Staehler et al., 
2005) 
 
 
Fig. 20.  Regulation of Hif1α by pVHL. In normoxic conditions, Hif1α is hydroxylated on 
prolyl and arginyl residues to allow pVHL binding and ubiquitin-mediated degradation.  
In hypoxic or VHL-/- conditions, VHL is unable to bind Hif1α for its degradation resulting 
in translation of angiogenic, metabolic, and proliferative proteins.   
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Angiogenic factors induced by HIF action include a high number of angiogenic 
genes including vascular endothelial growth factor (VEGF) as well as platelet-
derived growth factor (PDGF).  RCC tumor cells secrete high levels of VEGF 
that interacts with three different transmembrane tyrosine kinase receptors: 
VEGFR-1, VEGFR-2, and VEGF-R3 (Staehler et al., 2005).  VEGFR ligand 
binding results in autophosphorylation of transmembrane tyrosine kinase 
receptors and activation of downstream signaling pathways involving 
phospholipase Cγ, PI3K, Ras GTPase-activating protein and MAPK among 
others (Zeng et al., 2001).  RCC tumors overexpress VEGF type VEGFA that 
binds to similarly overexpressed VEGFR-1 (Flt-1), VEGFR2 (KDR/Flk-1) and the 
nonkinase receptor neropilin (NRP-1) (Mukhopadhyay et al., 1997).  VEGFA is a 
powerful vascular permeability agent and acts at a concentration of 1 mmol/L, 
nearly 50,000 times equivalent acting concentration for histamine (Senger et al., 
1983). The increase in vascular permeability results in leakage of plasma 
proteins including clotting proteins and fibrinogen into the tumor site.  
Subsequent activation of the clotting proteins results in deposition of fibrin in 
tumor stroma.  Fibrin leakage converts stroma with antiangiogenic character into 
highly angiogenic provisional stroma (Dvorak et al., 1985).  Downstream 
effectors of VEGF activity include induction of MMPs, nitric oxide synthase, 
mitogens, and antiapoptotic factors including bcl-2, survivin, and X-linked 
mammalian inhibitor of apoptosis (XIAP) (Dvorak, 2002).  PDGF interacts with 
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PDGR receptor (PDGFR) expressed on endothelial cell structural and support 
cells called pericytes.  PDGFR expression is important for later stages of blood 
vessel formation (Steahler et al., 2005). 
 
New therapies in phase III clinical trials are targeted against RCC 
overexpression of VEGF.  Mature vasculature endothelium is coated with 
periendothelial cells that secrete growth factors necessary to maintain 
angiogenic growth.  However, immature vasculature is dependent on VEGF 
signal for survival (Benjamin et al., 1999).  Therapy options for RCC were 
increased when it was discovered that established solid tumors had a high 
number of immature vessels still sensitive to VEGF inhibition.  Massive 
hemorrhage and necrosis result from VEGF withdrawal in glioma models of 
conditional VEGF expression (Benjamin and Keshet, 1997).  Bevacizumab 
(Avastin, Genetech) is a recombinant humanized monoclonal antibody against 
all VEGF isoforms that inhibits receptor binding (Presta et al., 1997).  In phase II 
trials against RCC in patients unresponsive to immunotherapy, time to 
progression was significantly longer in patients receiving bevacizumab than 
placebo (4.8 vs 2.5 months; Fig. 21; Yang et al., 2003).   
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Fig. 21.  Kaplan-Meier anaylsis of surivial free of tumor progression for patients 
receiving high dose bevazicumab (A) or low dose bevazicumab (B) as compared to 
placebo (Yang et al., 2003). 
 
  
In addition to increased expression of angiogenesis factors, HIF binding also 
results in induction of anaerobic metabolic activity.  Any tumor tissue greater 
than 100-200 µm from vasculature exists in hypoxic conditions, resulting in 
increased induction of HIF-1α. HIF-1α acts as a metabolic switch enabling cells 
to survive anaerobically on glucose by induction of glycolysis genes and 
inhibition of genes leading to oxidative phosphorylation (Kim et al., 2006).  
Upregulated genes include aldolase A, enolase 1, lactate dehydrogenaes A, 
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phosphofructokinase L, phosphofructokinase 1, and pyruvate kinase 1 among 
others (Fig. 22; Dang and Semenza, 1999). 
 
 
Fig. 22.  Regulation of hypoxia induced metabolic switches by HIF-1α.  In hypoxia 
HIF1α induces genes involved in, (1) conversion of glucose to pyruvate through 
glycolysis, (2) reduction of pyruvate to lactate, and (3) induction of pyruvate 
dehydrogenase kinase (PDK) to block pyruvate progression into Krebs cycle and 
subsequent ROS generation. Modified from Kim et al., 2006. 
 
 
Proliferative factors induced by HIF activity include transforming growth factor-α 
(TGF-α) and epidermal growth factor receptor (EGFR).  TGF-α has an unusual 
role in RCC in addition to an established role in angiogenesis since TGF-α acts 
as a mitogenic factor.  Unusually, cell proliferation of both VHL+/+ and VHL -/- 
RCC cells is suppressed by contact inhibition.  The importance of the mitogenic 
action of TNF-α is underscored by the observation that in the absence of 
external growth factors, proliferation of RCC can be blocked by inhibition of 
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TGF-α or it’s receptor epidermal growth factor receptor (EGFR; Fig. 23; de 
Paulsen et al., 2001).   
 
 
Fig. 23.  Growth inhibitory effects of TFG-α antisense oligodeoxynucleotide on VHL-/- 
RCC cells.  Cells were grown in media containing either 10% serum or ITS (insulin, 
transferin and selenium) in the presence of TFG-α antisense nucleotide.  Inhibition of 
TFG-α  in the presence of ITS resulted in 2.2 and 1.8 fold decreases in cell proliferation 
that could be abolished by the addition of 10% serum or the addition of purified TFG-α    
(de Paulsen et al., 2001). 
 
 
Both EGF and TGF-α can bind EGFRα and downstream effectors include Ras 
that constitutively activates the Raf/MEK/ERK pathway.  Raf controls the 
expression of over 120 genes involved in promotion of cell transformation, 
proliferation, invasion and adhesion (Staehler et al., 2005).  Tyrosine kinase 
inhibitors directly targeted against the EGFR have been studied in phase III trials 
and have delayed time to progression by only 4 weeks (15.1 weeks vs. 11.1 
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weeks) indicating that action of EGFR/TGF-α feedback loop is more complicated 
in vivo (Vogelzang and Sternberg, 2007).  
 
Peroxisome Proliferator-Activated Receptor-γ.  Many molecular targets are 
being explored outside of the VHL gatekeeper pathway including activation of 
peroxisome proliferator-activated receptors-γ (PPARγ).  PPARγ is a member of 
the nuclear hormone receptor superfamily (Isseman and Green, 1990).  Upon 
ligand binding PPARγ heterodimerizes with retinoid X receptor (RXR) and binds 
to PPARγ response elements (PPRE) within the genome (Palmer et al., 1995).  
PPARγ activity has been correlated with antineoplastic and anti-inflammatory 
responses in tumor cell lines including lung, breast, colon, prostate, 
osteosarcomas, and acute myelogenous leukemia.  Although PPARγ activity has 
been linked to many of the above functions, PPARγ agonists also display many 
other surprising actions unrelated to PPARγ expression, the so-called PPARγ 
independent effects (Yuan et al., 2006).  These PPARγ independent activities 
constitute many of the antineoplastic responses observed for diverse PPARγ 
agonists.   
 
PPARγ and NSAID Activated Gene-1.  In addition to antiproliferative actions, 
PPARγ ligands induce NSAID activated gene-1 (NAG-1), a protein implicated in 
apoptosis in various tumor cell lines (Chintharlapalli et al., 2005b).  NAG-1 is a 
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divergent member of the TGF-β superfamily and has also been named 
macrophage inhibitory cytokine-1 (MIC-1), placental transformation factor (PDF), 
growth differentiation factor 15 (GD15), and placental bone morphogenic protein 
(PLAB) (Baek and Eling, 2006).  NAG-1 is formed as a proprotein consisting of 
167 amino acids and undergoes proteolytic cleavage to generate a 112 amino 
acid secretory product (Bauskin et al., 2000).  Mature NAG-1 is expressed at 
high levels in the placenta and at lower levels in the kidney, colon, and prostate 
(Paralkar et al., 1998).  Many structurally diverse compounds can induce NAG-1 
including COX inhibitors, dietary agents, PPARγ agonists and anti-cancer drugs 
(Table 3; Eling et al., 2006). 
 
 
Table 3: Select NAG-1 inducers.  Modified from Eling et al., 2006. 
Concentration (uM)
Cyclooxygenase Inhibitors
Aspirin 1,000-10,000
Sulindac Sulfide 1-50
Diclofenac 50-200
ibuprofen 100-1,000
Dietary Agents
Resveratrol 10-100
Caspsaicin 10-100
Indol 3-carbinol 50
Genesitein 10-100
Lycopene 10-100
PPARg agonists
Troglitazone 5
DIM 20
C-DIM 5-10
Anti-Cancer Drugs
2F-203 .01-5
 
 
 
 
Interestingly, NAG-1 induction by COX inhibitors appears to be COX-
independent.  For example, in the COX negative HCT-116 cell line induction of 
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NAG and it’s proapoptotic effects are observed (Eling et al., 2006).  The 
biological functions of NAG-1 are still widely unknown but are thought to emulate 
those of other TGF-β family members.  NAG -1 has shown potential both as an 
anti-inflammatory and antiproliferative agent.  Ectopic expression of NAG-1 can 
result in cancer cell growth arrest in soft agar and retroviral expression inhibits 
MCF-7 breast cancer cell growth (Baek et al., 2001; Li and Jee, 2000).  
Heterozygous C57BL/6J-ApcMin/+ mice are prone to develop tumors of the 
stomach, colorectal axis and esophagus and were crossed with LOX-P-NAG-1 
transgenic mice.  When these mice are crossed with Protamine-Cre mice, NAG-
1 is overexpressed in all tissues   Upon treatment with the colon carcinogen 
azoxymethane (AOM), ApcMin/+/NAG+/- mice showed a 58% reduction in 
numbers of small intestinal polyps and a 60% reduction in tumor load (Fig. 24; 
Baek et al., 2006). 
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Fig. 24.  Production of NAG-1 transgenic mice.  Modified from Baek et al., 2006. 
 
 
The NAG-1 promoter is regulated by diverse elements including p53, early 
growth response-1 (EGR-1), chicken ovalbumin upstream promoter-transcription 
factors (COUP-TF1), specificity protein 1 (Sp1), and activating transcription 
factor 3 (ATF3) (Baek et al., 2001).  Interestingly, EGR-1 and Sp1 share the 
same binding site and in the presence of NAG-1 inducers, EGR-1 is also 
induced and preferentially binds the NAG-1 promoter (Chintharlapalli et al., 
2005b).  In addition to transcriptional regulation, NAG-1 is subject to post-
transcriptional modifications for example, the NAG-1 inducer retinoid 6-[3-(1-
adamantyl)-4-hydroxyphenyl]-2-napthalene carboxylic acid (AHPN) increases 
NAG-1 RNA stability (Newman et al., 2003).  ATF3 is a member of the 
ATF/CREB (cAMP response element binding protein) subfamily of the basic-
region leucine zipper (bZIP) family of transcription factors (Hai and Hartman, 
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2001).  ATF3 regulation of the NAG-1 promoter element has been shown in a 
study in which the transfection of ATF3 can increase NAG-1 induction by 3-fold.  
The potential ATF3 binding sequence on the NAG-1 promoter is TGACGTCA, a 
sequence which is identical to the CRE consensus sequence (Lee et al., 2006).   
 
PPARγ and Caveolin-1.  PPARγ agonists have been shown to induce caveolin-
1 expression in prostate cancer cells (Chintharlapalliet al., 2006).  Caveolin-1 is 
a membrane scaffolding protein and a major structural and functional component 
of lipid microdomains in the plasma membrane called caveolae (Razani et al., 
2002).  In the kidney, caveolae are found in the basolateral membrane of the 
distal collecting tubule, collecting duct, parietal cells of Bowman’s capsule, 
endothelial cells and smooth muscle cells (Breton et al., 1998).  Caveolae 
compartmentalize signal transduction receptors like EGFR, PDGFR and G-
protein, Ha-Ras to facilitate crosstalk (Carrion et al., 2003).  In tumors, caveolin 
has been linked to both tumor suppressive and oncogenic functions.  As a tumor 
suppressor, expression of recombinant caveolin-1 inhibits growth in breast, lung, 
and ovarian cancer cells and the caveolin gene located on 7q31.1 is often lost in 
many human cancers including RCC (Campbell et al., 2003; Engelman et al., 
1999).  However, caveolin acts as an oncogene in prostate cancer in which 
expression of caveolin-1 was found to be sufficient for growth and survival (Tahir 
et al., 2001).  Oncogenic activities are mechanistically explained by the fact that 
caveolin-1 activates MMP action to stimulate plasminogen synthesis of plasmin, 
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a molecule linked to extracellular matrix degradation (Campbell et al., 2003).  In 
RCC, studies confirm that caveolin acts as a mediator of metastasis and 
increased levels are linked with poor prognosis (Carrion et al., 2003). 
 
PPARγ and Cell Cycle Regulation.  The cell cycle progresses through distinct 
phases of growth; G1 phase allows growth in preparation for the S (synthesis) 
phase during which the DNA is replicated.  The S phase leads into the G2 phase 
allowing time for cell growth before the M (Mitosis) stage and the restart of the 
cell cycle at G1.  Cell cycle checkpoints allow the cell to exert control over the 
cell cycle and arrest at G1 if the cellular mass is too little or if DNA damage has 
occurred.  Most mutations involved in tumorigenesis affect the restriction point 
which occurs mid-G1 after this checkpoint cells are independent of growth 
factors and are commited to cell division (Pardee, 1974).  Ninety percent of 
human cancers have mutations affecting the coordinated regulation of 
retinoblastoma (Rb) protein by cyclin D1, D2, and D3 and cyclin E1 and E2 
which partner with cyclin dependent kinases (cdks) (Malumbres and Barbacid, 
2001).  In normal cells, cyclin D binds and activates cdk 4 and 6 while cyclin E 
binds to activate cdk2.  Cdk protein concentrations are stable throughout the cell 
cycle and activities are inhibited by phosphorylation on threonine and tyrosine 
residues.  The p21cip1 family regulates Cdk phosphorylation for inhibition of 
kinase activity and consists of three different members, p21cip1, p27kip1 and 
p57kip2.  In cancer both p21 and p27 actions are described as both oncogenic 
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and tumor suppressive depending on the cellular location (Swanton, 2004).  In 
colon cancer, patients with low or nondetectable p27 have 50% less survival 
time than patients with high p27 expression, in addition low p27 expression is 
correlated to poor cellular differentiation and prognosis in breast cancer (Loda et 
al., 1997; Catzavelos et al., 1997).  However, deletion of p27 is a rare event in 
cancer indicating that sometimes this protein can have oncogenic actions.  For 
example, in breast cancer cell lines, phosphorylation of p27 resulting in 
cytoplasmic localization, a condition associated with direct anti-apoptotic 
functions by binding of p27 to caspase 3 leading to inhibition of apoptosis 
(Swanton, 2004).  Passage by the restriction point is coordinated by 
hyperphosphorylation of Rb leading to the cessation of its replication 
suppressive actions.  Rb protein suppresses replication by the recruitment of 
histone deacetylase to E2F sites resulting in tighter association between DNA 
and nucleosomes and recruitment of SWI/SWF complexes.  Cyclin D1 interacts 
with cdk 4 and 6 to phosphorylate and inactivate Rb protein allowing replication 
to proceed (Swanton, 2004).  Cyclin D1 is negatively regulated by GSK-3β 
phosphorylation that marks cyclin D1 for cytoplasmic localization and ubiquitin 
mediated degradation and p21 and p27 inhibit nuclear translocation of the cyclin 
D1/cdk4 complex (Fig. 25; Lin et al., 2000).  
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Fig. 25.  Cell cycle regulation.  In repressive conditions, cyclin D1 is inhibited by 
phosphorylation by GSK-3β which enhances ubiquitin-mediated degradation and 
activity by p21 and p27.  In replication activating conditions, p21 and p27 are 
phosphorylated and translocated to the cytoplasm.  Nuclear cyclin D1 
hyperphosphorylates Rb protein to activate replication. 
 
 
Treatment of RCC cell lines with PPARγ agonists (pioglitazone and troglitazone) 
can increase growth arrest in G1 phase and repress expression of Rb, cyclin D, 
and cdk4 while inducing p21 and p27 (Yang et al., 2005). 
 
PPARγ and ER Stress-Dependent Apoptosis.  HIF-1α regulation of 
metabolism allows tumor cells to grow in hypoxic conditions but the metabolic 
switch from oxidative phosphorylation to glycolysis results in a deficit of 34 ATP 
/glucose molecule.  Consequently, many tumors including those found in the 
breast, lung, gastric system and prostate suffer from severe depletion of glucose 
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and oxygen leading to constitutive induction of HIF-1α independent unfolded 
protein response (UPR) pathway also called the ER stress response (Li et al., 
2006).  
 
The UPR proceeds in 2 main phases generating first a protective response and 
then upon acute stimuli ER stress-dependent apoptosis (Koumenis, 2006).  
Induction of ER-stress dependent glucose regulated protein -78 (GRP78) results 
in decreased translational activity coupled with selective translation of ER 
chaperone proteins and induction of ER-associated degradation pathways (Li et 
al., 2006).  GRP78 is a member of the HSP70 family of proteins and is 
overexpressed in many tumor types due to higher glucose utilization rates of 
cancer cells compounded by hypoxia (Koong et al., 1994; Dong et al., 2004).  A 
secondary, ER stress-dependent apoptotic pathway is induced in response to 
acute ER stress stimuli.  CHOP, also known as growth arrest and DNA damage-
inducible gene (GADD153) is a member of the CCAAT/enhancer binding 
proteins (C/EBPs).  ER stress dependent induction of CHOP leads to cell cycle 
arrest and/or apoptosis and serves as a marker for induction of ER stress-
dependent apoptosis (Oyadomari and Mori, 2004).   
 
Several models have been proposed for ER stress-dependent apoptosis.  In 
apoptosome deficient cells, release of Ca2+ is essential for downstream 
apoptosis in response to the classical ER stress inducer tunicamycin (Sano et 
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al., 2006).  In one model, release of Ca2+ from the ER leads to mitochondrial 
uptake of Ca2+ and release of cytochrome c.  It is not known if the release of 
cytochrome c from the mitochondria is essential for ER stress however, it is 
known that certain types of ER stress can be blocked by bcl-2 indicating that 
mitochondrial depolarization plays a large role in this ER stress induced 
apoptosis.   
 
In this laboratory it has been shown that ER stress is induced in cancer cells 
treated with both classical UPR activators and peroxisome proliferator activated 
receptor-γ (PPARγ) agonists called C-substituted dindolylmethane (DIM)s.  This 
reponse results in the induction of CHOP and it’s binding as a transcription 
factor to the DR5 promoter causing an upregulation of the DR5 gene.  It is 
hypothesized that overexpression of the death receptor induces dimerization 
and subsequent activation of caspase 8 dependent apoptosis (Fig. 26; 
Abdelrahim et al., 2006).   
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Fig. 26.  ER stress-dependent apoptosis.  C-DIM treatment results in ER-stress-
dependent apoptosis through the induction of CHOP and it’s subsequent induction of 
DR5.  Increased expression of DR5 results in autodimerization and binding of 
procaspase 8 and the caspase cascade.  Modified from Abdelrahim et al., 2006. 
 
 
The overexpression of the UPR protective response by cancer cells is an 
interesting new molecular target for cancer therapy.  Researchers are now 
attempting to facilitate the switch from protective UPR to ER-stress dependent 
apoptosis either by inhibition of protective UPR genes (GRP78) and downstream 
effectors or new cancer treatments that impose acute ER stress and thus 
bypass the UPR response (Fig. 27; Abdelrahim et al., 2006; Li et al., 2006). 
 
Although PPARγ agonists show great promise for treatment of many diverse 
cancer cell types, until late 2005 no group had pursued research on the 
treatment of kidney cancer by PPARγ agonists.  In select renal cancer cells, it 
has been shown that PPARγ agonists inhibit cell proliferation, induce apoptosis, 
and induce anti-angiogenic effects in vitro (Yuan et al., 2005). Recently, PPARγ 
has been identified as a potential tumor suppressor gene in RCC as was 
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downregulated in tissue samples from 47 RCC patients (Yuan et al., 2006).  A 
rationale for PPARγ downregulation in RCC is unknown but the gene resides in 
chromosome 3p25 in which heterozygocity is commonly lost in RCC (Yuan et 
al., 2006).  Interestingly in RCC cells in culture, PPARγ expression does not 
correlate with growth inhibitory or proapoptotic effects induced by PPARγ 
agonists in renal cell lines indicating that PPARγ-independent responses may 
play an important role the activities of PPARγ agonists.   
 
ER-Stress Related Apoptosis
Unfolded Protein Response
Normal Cell
RCC Cell
ER stress Inducer
 
Fig. 27.  Rational for the targeting of ER stress-related apoptosis.  RCC cells exist in 
Unfolded Protein Response conditions while normal cells exist under decreased 
metabolic and oxygen burden.  Upon addition of ER stress inducers, normal cells can 
compensate with induction of the unfolded protein response however, cancer cells will 
be overwhelmed and will enter ER-stress related apoptosis. 
 
 
PPARγ agonists including thiazolidinediones and 15-deoxy-∆12,14-
prostaglandin J2 (PGJ2) induce cell cycle arrest and apoptosis in human renal 
cell carcinoma cell lines (Yang et al., 2005, Yuan et al., 2005, Yuan et al., 2006).  
Recent studies in this laboratory have identified a series of 1,1-bis(3’indolyl)-1-
(ρ-substitutedphenyl)methanes [PPARγ active C-substituted DIMs] that inhibit 
growth and induce apoptosis in various cancer cell lines (Fig. 28; Chintharlapalli 
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et al., 2006; Chintharlapalli et al., 2005b; Lei et al., 2006; Chintharlapalli et al., 
2006; Kassouf W et al., 2006). 
 
N
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X= C6H5, t-butyl, CF3
 
Fig. 28.  Structures of PPARγ-active C-substituted DIMs. 
 
 
 
PPARγ-active C-DIMs: Effects on RCC.  Peroxisome proliferator-activated 
receptor γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-
activated transcription factors (Berger and Moller, 2002; Mangelsdorf et al., 
1995).  PPARs are involved in an increasing number of physiological functions 
including regulation of lipid metabolism and homeostasis and they also play a 
role in metabolic diseases, atherosclerosis and cancer (Lee et al., 2003, 
Desvergne and Wahli, 1999; Escher and Wahli, 2000; Rosem and Piegelman, 
2001; Wilson et al, 2001; Fajas et al, 2001).  Fatty acids, prostaglandins and 
related compounds bind PPARs; however, the endogenous ligands for these 
receptors are not well defined (Corton et al, 2000).  PPARγ agonists such as the 
thiazolidinediones rosiglitazone and pioglitazone have been developed for 
treatment of type II diabetes due to their activity as insulin-sensitizing agent 
(Wilson et al., 2000; Moller, 2001) 
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PPARγ is highly expressed in many tumor samples and cancer cell lines derived 
from hematopoietic and non-hematopoietic tumors and PPARγ agonists have 
been extensively investigated as potential antitumor drugs (Ikezoe et al., 2001; 
Gupta et al., 2003; Brockman et al., 1998; Kato et al., 2004, Place et al., 2003; 
Qin et al., 2003; Gupta et al.,2001; Kitamura et al., 1999; Takahashi et al., 1999; 
Motomura et al., 2000; Chang et al., 2000, Elstner et al., 1998).  
Thiazolidinediones such as rosiglitazone, troglitazone and 15-deoxy-
∆12,14prostaglandin J2 (PGJ2) typically inhibit cancer cell growth.  This is 
accompanied by inhibition of G0/G1 to S phase progression, downregulation of 
cyclin D1, and induction of p21 and/or p27.  These compounds and other 
classes of PPARγ agonists such as 2-cyano-3,12-dioxoolean-1,9-dien-28-oic 
acid (CDDO) and related triterpenoids, and 1,1-bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes [methylene-substituted diindolylmethanes (C-
DIMs)] also induce apoptotic pathways in cancer cell lines and inhibit tumor 
growth in in vivo models.  Research in this laboratory has focused on PPARγ-
active C-DIM compounds containing p-substituted trifluoromethyl (DIM-C-
pPhCF3), t-butyl (DIM-C-pPhtBu), and phenyl (DIM-C-pPhC6H5) groups (Hong et 
al., 2004; Contractor et al., 2005; Chintharlapalli et al., 2005a; Chintharlapalli et 
al., 2005b; Abdelrahim et al., 2006; Lei et al., 2006; Chintharlapalli et al., 2007; 
Chintharlapalli et al., 2006).  These compounds induce PPARγ-dependent p21 
and caveolin-1 expression in pancreatic and colon cancer cell lines, respectively.  
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However, many of the induced responses are PPARγ-independent.  For 
example, C-DIMs induce endoplasmic reticulum (ER) stress in pancreatic and 
ovarian cancer cells, and this leads to constitutive activation of death receptor 5 
(DR5) and caspase 8-mediated apoptosis (Abdelraim et al., 2006).  In addition, 
C-DIMs induce receptor-independent downregulation of cyclin D1, increased 
expression of nonsteroidal anti-inflammatory drug induced gene 1 (NAG-1) and 
activating transcription factor 3 (ATF3; Chintharlapalli et al., 2005b). 
 
Previous studies have reported that PGJ2 and thiazolidinediones induce cell 
cycle arrest and apoptosis in human renal cell carcinoma (RCC) cell lines, and 
this study investigates the effects of PPARγ-active C-DIMs in ACHN and 786-0 
renal cell carcinoma cells (Yang et al., 2005; Yuan et al., 2005; Yuan et al., 
2006).   
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II. MATERIALS AND METHODS 
Cell Culture 
Human renal clear cell carcinoma cell lines ACHN and 786-0 were obtained from 
the American Type Culture Collection (Manassas, VA).  ACHN cells were 
maintained in MEM (Sigma, St. Louis, MO) supplemented with 10% fetal bovine 
serum (FBS) and 10 ml/L of 100X antibiotic/antimycotic solution (Sigma-Aldrich, 
St Louis, Mo). 786-0 cells were maintained in RPMI 1640 (Sigma) supplemented 
with 10% FBS, and 10 ml/L of 100X antibiotic/antimycotic solution.  Cells were 
maintained at 37°C in the presence of 5% CO2.  
 
Reagents 
Antibodies for DR5, cleaved PARP, cleaved caspases 3 and 8 were purchased 
from Cell Signaling (Beverly, MA).  Antibodies CHOP, GRP78, PPARγ, Cyclin 
D1, p27, caveolin and β-tubulin were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA), and NAG-1 antibody was obtained from Upstate 
(Charlottesville, VA).  p21 antibody was obtained from BD Pharmingen (San 
Diego, CA), and monoclonal β-actin was obtained from Sigma-Aldrich (St. Louis 
Mo).  Reporter lysis buffer and luciferase reagent for luciferase studies were 
supplied by Promega (Madison, WI). β-Galactosidase (β-Gal) reagent was 
obtained from Tropix (Bedford, MA), and Lipofectamine 2000 reagent was 
purchased from Invitrogen (Carlsbad, CA).  Western Lightning 
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Chemiluminescence reagent was from PerkinElmer Life and Analytical Sciences 
(Boston, MA).  MG132 was obtained from Sigma.  Z-VAD-FMK and Z-IETDFMK 
were obtained from BD Bioscience (San Diego, CA), and the C-substituted DIMs 
(C-DIMs) and T007 were prepared in this laboratory as described previously (28-
30).   
 
Plasmids 
The Gal4 reporter containing 5x Gal4 response elements (pGal4) was kindly 
provided by Dr. Marty Mayo (University of North Carolina, Chapel Hill, NC).  
Gal4DBD-PPARγ construct (gPPARγ) was a gift from Jennifer L. Oberfield 
(GlaxoSmithKline Research and Development, Research Triangle Park, NC).  
The GRP-78 promoter-luciferase construct contains 374 bp from the promoter 
and was provided by Dr. K. Park, Center for Molecular Medicine, Sungkyunkwan 
University (Seoul, Korea).  Human CHOP promoter constructs were provided by 
Dr. Pierre Fafournoux (Saint Genes, Champarelle, France). 
 
Cell Proliferation Assay   
ACHN (3 x 104 cells/mL) and 786-0 cells (1.5x 104 cells/mL were plated in 12-
well plates.  After cell attachment for 24 hr, the medium was changed to 
DMEM/Ham’s F12 media containing 2.5% charcoal-stripped FBS and either 
vehicle (DMSO) or the indicated compound.  Fresh media and compound were 
added every 48 hr, and representative samples were trypsinized and counted 
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using the Coulter Z1 cell counter (Beckman Coulter, Fullerton, CA).  Each 
experiment was done in triplicate and results are expressed as means ± S.E. for 
each determination. 
 
Western Blot Analysis 
Cell lysates were prepared using lysis buffer [50 mM HEPES, 0.5 M NaCl, 1.5 
mM MgCl2, 1 mM EGTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, and 5 µl/ml 
Protease Inhibitor Cocktail (Sigma Aldrich)].  The lysates were incubated on ice 
for 1 hr with intermittent vortexing followed by centrifugation at 20,000 g for 10 
min at 4°C.  Protein samples (60-100 µg) were size-separated by 
electrophoresis on sodium dodecylsulfate-polyacrylamide gels under non-
reducing conditions.  Separated proteins were electroblotted onto polyvinylidene 
membranes (polyvinylidene diflouride; Bio-Rad, Hercules, CA).  The blot was 
blocked by incubating in blocking buffer (5% skim milk, 10 mM Tris-HCL, 150 
mM NaCl, pH 8 and 0.1% Tween 20) for 1 hr at 20°C, and then incubated with 
the primary antibody overnight at 4°C.  Incubation with a horseradish peroxidase 
(HRP)-conjugated anti-mouse or rabbit secondary antibody was then carried out 
at 37°C for 1 hr, and antibody-bound proteins were detected by the ECL western 
blotting analysis system. 
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Transfection and Luciferase Assay 
Cells were cultured in 12-well plates DMEM/Ham’s F12 media containing 2.5% 
charcoal-stripped FBS.  After 16 - 20 hr, when cells were 50 - 60% confluent, 
reporter gene constructs were transfected using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA).  The effects of different treatments on transactivation were 
investigated on ACHN and 786-0 cells.  Cells were transfected with either 500 
ng of pGRP78, pCHOP, Gal4Luc and/or PPARγ-GAL4 constructs in the 
presence of 40 ng β-Gal according to the manufacturers protocol.  Five hr after 
transfection, the transfection mix was replaced with complete media containing 
either vehicle (DMSO) or the indicated ligand for 24 hr.  Cells were then lysed 
with 100 µl of 1X reporter lysis buffer, and 30 µl of cell extract was used for 
luciferase and β-Gal assays.  A lumicount luminometer (PerkinElmer Life and 
Analytical Sciences) was used to quantitate luciferase and β-Gal activities.  
Luciferase activities were then normalized to β-Gal activity. 
 
Animals and Orthotopic Implantation of Tumor Cells 
Male athymic nude mice (NCI-nu) were purchased from the Animal Production 
Area of the National Cancer Institute Frederick Cancer Research and 
Development Center (Frederick, MD).  The mice were housed and maintained 
under specific pathogen-free conditions in facilities approved by the American 
Association for Accreditation of Laboratory Animal Care and in accordance with 
current regulations and standards of the United States Department of 
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Agriculture, United States Department of Health and Human Services, and the 
NIH.  The mice were used in accordance with institutional guidelines when they 
were 8 - 12 wk old.  
 
To produce tumors, ACHN cells were harvested from subconfluent cultures by a 
brief exposure to 0.25% trypsin and 0.02% EDTA.  Trypsinization was stopped 
with medium containing 10% fetal bovine serum, and the cells were washed 
once in serum-free medium and resuspended in HBSS.  Only suspensions 
consisting of single cells with >90% viability were used for the injections.  
Injection of cells into the kidney subcapsule was performed.  Briefly, mice were 
anesthetized and placed in the left lateral decubitus position.  A vertical incision 
was made in the right flank through the skin and peritoneum, exposing the 
lateral aspect of the kidney.  The kidney was lifted gently and stabilized.  A 27-
gauge needle was inserted into the renal parenchyma from the lower pole of the 
kidney and advanced until its point reached just below the renal capsule.  At this 
time, the mice were injected with one million viable tumor cells in 50 µL HBSS.  
After injection, the kidney was returned to the abdominal cavity, and the wound 
was closed in one layer with wound clips.  
 
The mice were killed 5 wks after injection, normal and the injected kidneys were 
removed and fixed in 10% buffered formalin solution after measuring the weight.  
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Tumors usually grow in kidney subcapsules and invade into the kidneys cortex 
and medulla.  
 
TUNEL Assay and Histological Studies 
For H&E staining and TUNEL assay, tumor tissue was fixed in formalin and 
embedded in paraffin, one section was processed for H&E staining and the 
others were used for the TUNEL assay.  TUNEL staining was carried out using 
DeadEnd Colorimetric TUNEL System (Promega, Madison, WI).  Paraffin-
embedded sections (4-6 µM thick) were processed per manufacturer protocol.  
Briefly, sections were deparaffinized in xylene and then treated with a graded 
series of alcohol [100, 95, 85, 70 and 50% ethanol (v/v) in double distilled H20] 
and rehydrated in PBS (pH 7.5).  Tissues were then treated Proteinase K 
solution for permeabilization and then refixed with 4% paraformaldehyde 
solution.  Slides were then treated with rTdT reaction mix and incubated at 37°C 
for 1 hr.  Reaction was terminated by immersing the slides in 2 X SSC solutions 
for 15 min at room temperature.  After blocking the endogenous peroxidases 
activity (by 0.3% hydrogen peroxide) slides were washed with PBS and then 
incubated with Streptavidin HRP solution for 30 min at room temp.  After 
washing, slides were incubated with DAB (substrate) solution until a light brown 
background appeared (10 min) and then rinsed several times in deionized water.  
After mounting, slides were observed by light microscopy. 
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Statistical Analysis   
Statistical significance of protein expression and promoter activation was 
assessed using Student’s t-test. A value of P < 0.05 compared with solvent 
control was considered statistically significant. 
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III. RESULTS 
The growth inhibitory effects of PPARγ-active C-DIMs were investigated in both 
786-0 and ACHN renal carcinoma cell lines (Fig. 29).  IC50 values for growth 
inhibition by DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 were in the 1 - 
5 µM range in both cell lines.  However, ACHN cells appeared to be slightly 
more sensitive to the C-DIM compounds than 786-0 cells since significant 
growth inhibition was observed in the former cell line after treatment with 1.0 µM 
concentration.  These results indicted that C-DIMs were more potent than 
pioglitazone or PGJ2 which exhibited IC50 values from 10 - 20 µM in ACHN and 
Cak-1 cell lines (Yang et al., 2005; Yuan et al., 2005; Yuan et al., 2006)
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Fig. 29.  Inhibition of RCC growth by PPARγ-active C-DIMs.  ACHN and 786-0 cells were treated with DMSO or 1, 5 and 10 
µM DIM-C-pPhCF3 (A), DIM-C-pPhtBu (B), and DIM-C-pPhC6H5 (C) for up to 6 days.  The number of cells were determined 
on days 2, 4 and 6 as described in the Materials and Methods.  Results are expressed as means ± SE for three separate 
determinations for each treatment group.  Significant (p < 0.05) inhibition of cell growth in ACHN and 786-0 cells was 
observed at concentrations ≥ 1.0 and ≥ 5.0 µM, respectively.   
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Results in Figure 31A illustrated the effects of DIM-C-pPhtBu on activation of 
luciferase activity in ACHN and 786-0 cells transfected with the PPARγ-GAL4 
chimera and a reporter gene construct (pGAL4) containing five tandem yeast 
GAL4 response elements linked to a luciferase reporter gene.  The PPARγ-
GAL4 chimera contains the ligand binding domain of PPARγ linked to the DNA 
binding domain of the yeast GAL4 protein.  The results show that DIM-C-pPhtBu 
induced luciferase activity in both cell lines and induction was also observed for 
DIM-C-pPhCF3 and DIM-C-pPhC6H5 (data not shown).  In contrast, Western blot 
analysis of whole cell lysates from 786-0 and ACHN cells shows that PPARγ is 
highly expressed in the latter cell line, whereas low to non-detectable levels of 
PPARγ protein were detected in 786-0 cells (Fig. 30A).  Protein expression was 
not affected by treatment with 10 µM DIM-C-pPhtBu.  These data are consistent 
with a previous study showing highly variable expression of PPARγ in kidney 
cancer cell lines and tumors, and renal carcinoma is an example of a tumor type 
where decreased PPARγ expression in tumor vs. non-tumor tissue has been 
observed (Novick et al., 2002).
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Fig. 30.  Activation of PPARγ and cell cycle proteins by C-DIMs.  (A)  Activation of PPARγ-GAL4/GAL4-luc and PPARγ 
expression in ACHN and 786-0 cells.  ACHN and 786-0 cells were transfected with PPARγ-GAL4/GAL4-luc and treated with 
DMSO or C-DIMs.  Luciferase (relative to β-galactosidase) activity was determined as described in the Materials and 
Methods.  Results are expressed as means ± SE for three separate determinations for each treatment group.  Significant (p < 
0.05) induction is indicated by an asterisk.  Western blot analysis of whole cell lysates was determined as described in the 
Materials and Methods.  Analysis of p21, p27 and cyclin D1 in ACHN (B) and 786-0 (C) cells, and of cyclin D1 (D) in both cell 
lines.  Cells were treated with different compounds and DMSO (control), and proteins were analyzed by Western blot analysis 
of whole cell lysates as described in the Materials and Methods.  Results in B and C were quantitated from three separate 
experiments in which cyclin D1 levels (relative to β-tubulin) in the DMSO group were set at 1.0.  Significant (p < 0.05) 
inhibition of cyclin D1 protein is indicated by an asterisk. 
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PPARγ agonists typically affect cell cycle proteins such as cyclin D1, p27 and 
p21, and results in Figures 31B and 31C summarize the concentration- and 
time-dependent effects of DIM-C-pPhtBu on these same proteins in ACHN and 
786-0 cells, respectively.  p27 is uniformly expressed after 12 or 24 hr in ACHN 
cells and is unaffected by treatment with DIM-C-pPhtBu.  In contrast, p21 
expression is low after 12 hr and enhanced after 24 hr.  Some induction of p27 is 
observed only at the highest concentration (12.5 µM) of DIM-C-pPhtBu.  p21 is 
expressed in both cell lines and DIM-C-pPhtBu decreases expression of p21 in 
ACHN but not 786-0 cells.  In contrast, DIM-C-pPhtBu induced a significant 
decrease in the expression of cyclin D1 protein as previously observed in other 
cancer cell lines treated with PPARγ-active C-DIMs (Qin et al., 2004, 
Chintharlapalli et al., 2007; Chintharlapalli et al., 2006), and this response was 
reversed after cotreatment with the proteasome inhibitor MG132 (Fig. 30D). 
 
Previous studies show that caveolin 1 is induced in colon but decreased in 
prostate cancer cells (Chintharlapalli et al., 2005c, Chintharlapalli et al., 2006).  
DIM-C-pPhtBu decreased caveolin-1 in 786-0 cells but did not affect expression 
in ACHN cells (Fig. 31A).  Previous studies have also shown that the 
proapoptotic NAG-1 gene and ATF3 are induced by C-DIMs.  Results in Figure 
32B demonstrate that both proteins were induced by DIM-C-pPhtBu in ACHN 
and 786-0 cells, and up to a 4-fold induction response was observed (Fig. 31C).   
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Fig. 31.  Effects of C-DIM compounds on caveolin-1 (A), NAG-1 (B), and ATF-3 (C) 
expression in RCC cells.  Cells were treated with DMSO or C-DIM compounds, and 
whole cell lysates were analyzed by Western blot analysis as described in the Materials 
and Methods.  Quantitation of NAG-1 protein induction (C) was determined in three 
separate experiments, and results are expressed as means ± SE for NAG-1 (relative to 
β-tubulin) protein in the DMSO group (set at 1.0).  Significant (p < 0.05) induction of 
NAG-1 is indicated by an asterisk. 
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It has also been reported that C-DIM compounds activate receptor-independent 
ER stress and apoptosis in pancreatic and ovarian cancer cells (Abdelrahim et 
al., 2006; Lei et al., 2006).  Results in Figure 33A summarize the effects of DIM-
C-pPhtBu on ER stress pathways in ACHN and 786-0 cells.  Minimal induction 
of ER stress responses GRP78 and CHOP were observed after treatment of 
both cell lines for 6 hr (data not shown), whereas both markers of ER stress 
were elevated after treatment with DIM-C-pPhtBu for 12 or 18 hr and this 
persisted for up to 24 hr.  Similar induction responses were also observed for 
DIM-C-pPhCF3 and DIM-C-pPhC6H5 (data not shown).  In addition, a similar 
time-course was observed for induction of DR5 and cleaved caspase-8 which is 
indicative of activation of the extrinsic apoptotic pathway associated with 
induction of DR5.  There were minimal differences in constitutive and inducible 
GRP78, CHOP, DR5 and caspase-3 cleavage in ACHN and 786-0 cells, except 
that higher constitutive levels of DR5 were expressed in the former cell line.  
Figure 33B directly compares and quantitates induction of GRP78 and CHOP 
proteins in ACHN and 786-0 cells after treatment with 5 - 12.5 µM DIM-C-
pPhtBu for 18 hr.  Significant induction was observed in both cell lines using 10 
µM DIM-C-pPhtBu.   
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Fig. 32.  Activation of ER stress and apoptotic responses by C-DIMs in RCC 
cells.  (A)  Induction of ER stress responses by C-DIMs in ACHN and 786-0 
cells.  Cells were treated with DMSO or DIM-C-pPhtBu for 12 or 18 hr, and 
whole cell lysates were analyzed by Western blot analysis.  Minimal protein 
expression was observed after treatment for 6 hr, whereas the blot obtained 
using lysates treated for 24 hr was similar to that observed for the 18 hr 
treatment group (data not shown).  (B)  Quantitation of GRP78 and CHOP 
expression.  Cell lysates from three replicate experiments were analyzed as 
described in (A), and both GRP78 and CHOP proteins (relative to β-tubulin) in 
the DMSO group were assigned a relative value of 1.0.  Significant (p < 0.05) 
induction of these proteins by DIM-C-pPhtBu is indicated by an asterisk.  (C)  
Activation of pGRP78 and pCHOP constructs by C-DIMs.  ACHN or 786-0 cells 
were transfected with pGRP78 or pCHOP and treated with DMSO or DIM-C-
pPhtBu.  Luciferase (relative to β-galactosidase) activity determined as 
described in the Materials and Methods.  Results are expressed as means ± SE 
for three separate experiments for each treatment group, and significant (p < 
0.05) induction is indicated by an asterisk.  
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We also showed that 10 µM DIM-C-pPhtBu induced transactivation in ACHN 
and 786-0 cells transfected with pGRP78, a construct containing the -374 to +1 
region of the GRP78 gene promoter which has an ER stress response element 
(ERSE; Fig. 32C).  Similar induction of luciferase activity by DIM-C-pPhtBu was 
observed in cells transfected with pCHOP which contains the -954 to +1 region 
of the CHOP gene promoter. 
 
Activation of ER stress pathways and the subsequent induction of DR5 and 
cleaved caspase 8 (Fig. 32A) is consistent with the induction of RCC cell death 
observed after treatment with the C-DIM compounds (Fig. 29).  Results in Figure 
5A confirm that DIM-C-pPhtBu induced a concentration- and time-dependent 
induction of cleaved (activated) caspase-3 and caspase-dependent PARP 
cleavage in ACHN and 786-0 cells at concentrations of 5 and 7.5 µM with the 
maximal effects observed after 72 hr.  The role of PPARγ in mediating DIM-C-
pPhtBu-induced PARP cleavage, cyclin D1 downregulation, induction of NAG-1 
and GRP78 was investigated in ACHN and 786-0 cells treated with the C-DIM 
compound alone or in combination with the PPARγ antagonist T007 (Fig. 33A).  
The results show that T007 did not affect any to the DIM-C-pPhtBu-induced 
responses, suggesting that these effects were PPARγ-independent.  Similar 
results were observed in previous studies with C-DIMs in other cancer cell lines 
(Abdelrahim et al., 2006; Lei et al., 2006; Chintharlapalli et al., 2007, 
Chintharlapalli et al., 2006).  Results in Figures 34B and 34C also demonstrate 
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(quantitatively) that DIM-C-pPhtBu induced PARP cleavage in 786-0 and ACHN 
cell lines, respectively.  These responses were blocked after cotreatment with 
both a caspase-8 (Z-IETD-FMK) and a pancaspase (Z-VAD-FMK) inhibitor.  
These results confirm that DIM-C-pPhtBu induces caspase-8 and caspase-3-
dependent apoptosis in both ACHN and 786-0 cells.  This is consistent with 
activation of ER stress (Fig. 32) and other proapoptotic genes such as NAG-1 
and ATF3. 
 
We also investigated the effects of DIM-C-pPhtBu on renal adenocarcinoma 
development in an orthotopic model for kidney cancer in which ACHN and 786-0 
cells were directly injected into the kidney.  Preliminary studies showed that 
ACHN but not 786-0 cells formed tumors in this model.  Figure 6 illustrates the 
effects of DIM-C-pPhtBu (40 mg/kg/d) and corn oil vehicle control on normal 
kidney weights and kidney weights in tumor-bearing animals.  Normal kidney 
weights in animals administered corn oil or DIM-C-pPhtBu were 0.262 ± 0.047 
and 0.274 ± 0.03, respectively, and kidney weights in tumor-bearing animals 
were 0.752 ± 0.08 and 0.444 ± 0.07, respectively (Figs. 35A and 35B).   
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Fig. 33.  Induction of apoptosis and role of PPARγ in mediating effects of C-DIMs in 
RCC cells.  (A)  Induction of caspase 3 and PARP cleavage by C-DIMs.  Cells were 
treated with DMSO and 5 or 7.5 µM DIM-C-pPhtBu for 24 or 72 hr.  Whole cell lysates 
were analyzed by Western blot analysis as described in the Materials and Methods.  (B)  
Effects of T007 on C-DIM-induced responses.  Cells were treated with DMSO, 12.5 µM 
DIM-C-pPhtBu, and 10 µM T007 alone or in combination for 24 hr.  Whole cell lysates 
were analyzed by Western blot analysis as described in the Materials and Methods.  
Similar results were observed in duplicate experiments.  Effects of caspase inhibitors on 
DIM-C-pPhtBu-induced PARP cleavage in ACHN (C) and 786-0 (D) cells.  Cells were 
treated for 72 hr as indicated in (A), and cleaved PARP in DMSO-treated cells (relative 
to β-tubulin) was set at 1.0.  Treatment with DIM-C-pPhtBu significantly induced PARP 
cleavage in both cell lines.  Results for all treatment groups are given as means ± SE 
for three replicate experiments, and both caspase-8 (Z-IETD-FMK) and pancaspase (Z-
VAF-FMK) inhibitors significantly inhibited (*) DIM-C-pPhtBu-induced PARP cleavage. 
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Fig. 34.  DIM-C-pPhtBu inhibits tumor growth in an orthotopic model for renal 
adenocarcinoma.  Representative kidney/tumors (A) and weights (B).  Weights of 
kidneys and kidneys + tumors from mice treated with corn oil (controls) or DIM-C-
pPhtBu (40 mg/kg/d) were determined after sacrifice.  A significant (p < 0.05) decrease 
in kidney + tumor weight in animals treated with DIM-C-pPhtBu is indicated by an 
asterisk.  Kidney (± tumor) weights are means ± SE for at least 5 animals per treatment 
group.  Hematoxylin and eosin staining (C) and TUNEL staining (D) in kidneys/kidney 
tumors.  Hematoxylin and eosin staining of tumor and non-tumor tissue from mice 
bearing human ACHN tumors and TUNEL staining of kidney tumors from corn oil and 
DIM-C-pPhtBu-treated mice was carried out as described in the Materials and Methods.  
Similar results were observed in replicate experiments. 
 
 
 
Thus, DIM-C-pPhtBu had no affect on kidney weights but significantly decreased 
kidney tumor weights in animals bearing ACHN cells.  Hematoxylin and eosin 
staining of kidney tumors and non-tumor tissue showed distinct differences.  The 
normal kidney (Fig. 6C, upper) consists of low numbers of glomerulas 
surrounded  by normal appearing tubular epithelium, whereas the appearance of 
tumor tissue contained neoplastic cells with atypical epithelium with variable 
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malignant features (Fig. 34C, lower).  In addition, using the TUNEL assay, it was 
apparent that DIM-C-pPhtBu induced massive staining in the tumors compared 
to corn oil (control) tumors demonstrating that apoptosis was induced in both 
ACHN tumors (Fig. 34D) and cells.  This was a major pathway for the 
anticarcinogenic activity of DIM-C-pPhtBu in this kidney cancer model and is 
consistent with the PPARγ-independent activation of apoptosis by C-DIMs in 
RCC cells (Figs. 33 and 34). 
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IV. DISCUSSION AND CONCLUSIONS 
Renal cell carcinoma is a complex disease and the most predominant form is 
clear cell carcinoma which is highly metastatic and resistant to many 
chemotherapies.  Interferon and interleukin-2 have been used for treatment of 
metastatic renal cell carcinoma; however, only 15 - 20% of patients benefit from 
these treatments (Novick et al., 2002).  Renal cell carcinoma typically exhibits 
high expression of hypoxia-inducible factor 1α (HIF-1α) and upregulation of 
vascular endothelial growth factor (VEGF) expression, and newer 
chemotherapies for treatment of renal cell carcinoma are targeting VEGF/VEGF 
receptor signaling using antibodies and kinase inhibitors (Motzer et al, 2006).   
 
PPARγ is an orphan nuclear receptor that is overexpressed in many tumor types 
and different structural classes of PPARγ agonists show some promise for 
cancer chemotherapy (Ikezoe et al., 2001, Fajas et al., 2001).  For example, 
both thiazolidinediones and PGJ2 inhibit growth of renal cell carcinoma cells and 
typically affect cell cycle genes/proteins associated with G0/G1 to S phase 
progression (Yang et al., 2005; Yuan et al., 2005).  However, unlike many 
cancer cell lines and tumors, there is some suggestion that the overexpression 
of PPARγ in renal cell carcinoma is somewhat variable (Yuan et al., 2006).  For 
example, in a study of six renal cell carcinoma cell lines, the expression of 
PPARγ was lower in five of these cell lines compared to normal kidney tissue.  
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Only ACHN cells expressed PPARγ mRNA levels higher than observed in 
normal kidney cells.  Similar results were observed in the comparison of PPARγ 
mRNA in renal cell carcinoma tumors vs. normal kidney tissue where the tumor 
samples frequently exhibited lower levels of this transcript. 
 
Studies in our laboratory have identified a novel class of PPARγ agonists 
derived from DIM and, like many other ligands for PPARγ, the C-DIM 
compounds inhibit cancer cell/tumor growth through receptor-dependent and -
independent pathways (Abdelrahim et al., 2006; Lei et al., 2006; Chintharlapalli 
et al., 2007; Chintharlapalli et al., 2006).  Results of growth inhibitory studies in 
ACHN and 786-0 renal cell carcinoma cells showed that IC50 values for PPARγ-
active C-DIMs were between 1 - 5 µM in both cell lines, and this was much lower 
than observed for pioglitazone or PGJ2 in other studies (Yuan et al., 2006).  
These results suggest that C-DIM compounds are potentially effective drugs for 
treatment of renal cell carcinoma.  Moreover, due to the differential expression of 
PPARγ protein in ACHN (high) vs. 786-0 (low to non-detectable) (Fig. 30A), 
these cell lines are ideal for investigating activation of receptor-dependent and -
independent growth inhibitory/proapoptotic pathways by C-DIMs.  In 
transactivation studies using a PPARγ-GAL4 chimera, we observed induction 
responses by DIM-C-pPhtBu (Fig. 30) in ACHN and 786-0 cell lines, suggesting 
that the appropriate cofactors required for this response are expressed in both 
cell lines.  The effects of PPARγ-active C-DIMs on p27 and p21 were highly 
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variable in ACHN and 786-0 cells (Figs. 31B and 31C).  However, DIM-C-
pPhtBu induced proteasome-dependent degradation of cyclin D1 (Fig. 30) which 
was not inhibited after cotreatment with a PPARγ antagonist (Fig. 33B).  These 
results are consistent with previous reports showing that C-DIMs induce 
receptor-independent degradation of cyclin D1 in other cancer cell lines (Qin et 
al., 2004; Chintharlapalli et al., 2007; Chintharlapalli et al., 2006).  PPARγ-active 
C-DIMs induce receptor-dependent expression of caveolin-1 in colon cancer 
cells, where this gene may exhibit tumor suppressor activity, but decrease 
caveolin-1 in prostate cancer cells, where it may have tumor-enhancing activity 
(Chintharlapalli et al, 2006; Bender et al., 2000; Chintharlapalli et al., 2007; Yang 
et al., 1998; Williams et al., 2005).  Caveolin-1 overexpression in renal cell 
carcinoma patients predicts poor disease-free survival; however, the functional 
role of caveolin-1 in renal cell carcinoma has not been explored (Campbell et al., 
2003).  In our studies, 7.5 µM DIM-C-pPhtBu decreased caveolin-1 expression 
in 786-0 but not in ACHN (no change) cells (Fig. 31A), and resembled the 
responses observed in prostate cancer cells where PPARγ-active C-DIMs 
decrease levels of caveolin-1 protein (Chintharlapalli et al., 2007).  The function 
of this effect of DIM-C-pPhtBu (i.e. decreased caveolin-1 expression) in renal 
cell carcinoma cells is now being further investigated. 
 
PPARγ-active C-DIMs also induce NAG-1 and ER stress in colon and pancreatic 
cancer cells.  These receptor-independent responses lead to apoptosis.  Results 
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summarized in Figures 32 - 34 show that DIM-C-pPhtBu also induced NAG-1 
and ER stress proteins and DR5, and these responses are coupled with 
activation of caspase-dependent PARP cleavage.  This suggests that DIM-C-
pPhtBu-induced apoptosis in renal cell carcinoma cells is similar to that 
observed in colon and pancreatic cells and these responses are PPARγ-
independent (Chintharlapalli et al., 2005b; Abdelrahim et al., 2006; Lei et al., 
2006; Chintharlapalli et al., 2006) (Fig. 33B).   
 
We also used an orthotopic model of renal cell carcinoma and directly injected 
human ACHN cells into the kidney of each athymic mouse.  The results in 
Figures 35A and 35B show that treatment with DIM-C-pPhtBu (40 mg/kg/d) did 
not affect normal kidney weight but significantly decreased the weight of the 
tumor-bearing kidney.  Hematoxylin and eosin staining of normal kidney and 
kidney tumors exhibited the expected differences in staining, and the TUNEL 
assay demonstrated extensive staining for apoptosis in the treated animals but 
not in the controls (Fig. 34C).  These results demonstrate a parallel mode of 
action between the in vivo and in vitro studies where DIM-C-pPhtBu inhibits both 
RCC cell and tumor growth and this is due, in part, through activation of 
apoptosis.  Thus, DIM-C-pPhtBu, a prototypical C-DIM compound represents a 
novel class of drugs for treatment of renal tumors through PPARγ-independent 
activation of proapoptotic proteins (NAG-1) and pathways (ER stress).  Current 
studies are focused on identifying the most active proapoptotic C-DIM analogs 
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(among over 100 compounds) for potential clinical applications in treating renal 
cell carcinoma.  
 110 
 
REFERENCES 
Abdelrahim M, Newman K, Vanderlaag K, Samudio I and Safe S (2006) 
3,3’Dinindoloylmethan (DIM) and its derivatives induce apoptosis in 
pancreatic cancer cells through endoplasmic reticulum stress-dependent 
upregulation of DR5. Carcinogenesis 27:171-728.  
Ahmed A and Anders M (1978) Metabolism of dihalomethanes to formaldehyde 
and inorganic halide. II. Studies on the mechanism of the reaction. Biochem 
Pharm 27:2021-2025.  
Akhurst R and Derynck R (2001) TGF-beta signaling in cancer- a double edged 
sword. Trends Cell Biol 11:S44-51. 
Alper S (2002) Genetic Diseases of acid-base transports. Ann Rev Physiol 
64:899-923. 
Anders M (1980) Metabolism of drugs by the kidney. Kidney Int 18:636-647.  
Anders M (2004) Glutathione-dependent bioactivation of haloalkenes and 
haloalkanes. Drug Metab Rev 36:583-594.  
Apiwattanakul N, Sekine T, Chairoungdua A, Kanai Y, Nakajima N, Sophasan S 
and Endou H (1999) Transport properties of nonsteroidal anti-inflamatory 
drugs by organic anion transport 1 expressed in Xenopous laevis oocytes. 
Mol Pharmacol 55:847-854.  
Ashkenazi A and Dixit V (1998) Death receptors: signaling and modulation. 
Science 281:1305-1308. 
 111 
 
Baek S and Eling T (2006) Changes in gene expression contribute to cancer 
prevention by COX inhibitors. C Prog Lipid Res 45:1-16. 
Baek S, Horowitz J and Eling T (2001) Molecular cloning and characterization of 
human non-steroidal anti-inflamatory drug –activated gene promoter.  Basal 
transcription is mediated by Sp1 and Sp3. J Biol Chem 276:33383-33392. 
Baek S, Okazaki R, Lee S, Martinez J, Kim J, Yamaguchi K, Mishina Y, Martin 
D, Schoieb A, McEntee M and Eling T (2006) Nonsteroidal anti-inflamatory 
drug activated gene-1 overexpression in transgenic mice suppresses 
intestinal neoplasi. Gastrointerology 131:1553-1560. 
Bachschmid M, Schildknecht S and Ullrich V (2005) Redox regulation of 
vascular prostanoid synthesis by the nitric oxide-superoxide system. Biochem 
Biophys Res Commun 338:536-542. 
Bauskin A, Brown D, Junankar S, Rsaih K, Eggleton S, Hunter M, Liu T, Smith 
D, Kuffner T and Pankhurst G et al. (2000) The propeptide of macrophage 
inhibitory citokine (MIC-1), a TGB-beta superfamily member, acts as a quality 
determinant for correctly folded MIC-1. Embo J 19:2212-2220. 
Bender FC, Reymond MA, Bron C, Quest AF (2000) Caveolin-1 levels are down-
regulated in human colon tumors, and ectopic expression of caveolin-1 in 
colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60:5870-
5878. 
 112 
 
Benjamin L, Golijanin D, Itin A, Pode A and Keshet E (1999) Selective ablation 
of immature blood vessels in established human tumors follows vascular 
endothelial growth factor withdrawal. J Clin Invest 103:159-165. 
Benjamin L and Keshet E (1997) Conditional switching of vascular endothelial 
growth factor (VEGF) expression in tumors: Induction of endothelial cell 
shedding and regression of hemangioblastoma-like vessels by VEGF 
withdrawal. Proc Natl Acad Sci 94:8761-8766. 
Berger J and Moller DE (2002) The mechanisms of action of PPARs. Annu Rev 
Med 53:409-35. 
Bergstrom A, Hsieh S, Lindblad P, Lu, C, Cook N and Wolk A (2001) Obesity 
and renal cell cancer- a quantitative review. Br J Cancer 85:984-990. 
Bichler K and Wechsel H. (1999) The problematic nature of metastasized renal 
cell carcinoma. Anticancer Res 19:1462-1466. 
Bleumer I, Oosterwijk E, de Mulder P and Mulders P (2003) Immunotherapy for 
renal cell carcinoma. Eur Urol 44:65-75. 
Boogard P, Commandeur J, Mulder G, Vermeulen N, Nagelkerke J (1989) 
Toxicity of the cysteine-S-conjugates and mercapturic acids of four structurally 
related diflouroethylenes in isolated proximal tubular cells from rat kidney.  
Uptake of the conjugates and activation to toxic intermediates. Biochem 
Pharmacol 36: 654-663. 
Bottinger E and Bitzer M (2001) TGF-beta signaling in renal disease. J Am Soc 
Nephrol 13:2600-2610. 
 113 
 
Brauch H, Weirich G, Klein B, Rabstein S, Bolt H and Bruning T (2004) VHL 
mutations in renal cell cancer: does occupational exposure to 
trichloroethylene make a difference. Toxicol Letters 151:301-310.  
Brenner B (1976) Transport of molecules across renal glomerular capillaries. 
Physiol Rev 56:502-534.  
Breton S, Lisanti M, Tyszkowski R, McLaughlin M, Brown D (1998) Basolateral 
distribution of caveolin-1 in the kidney.  Absence from H+-atpase-coated 
endocytic vesicles in intercalated cells. J Histochem Cytochem 46:205-214.  
Brockman JA, Gupta RA and DuBois RN (1998) Activation of PPARg leads to 
inhibition of anchorage independent growth of human colorectal cancer cells. 
Gastroenterology 115:1049-1055. 
Bui M, Seligson D, Han K, Pantuck A, Dorey F, Huang Y, Horvath S, Leibovich 
B, Chopra S, Liao S, Stanbridge E, Leman M, Palotie A, Figlin R,  Belldegrun 
A (2003) Carbonic anhydrase IX is an independent predictor of survival in 
advanced renal clear cell carcinoma. Clin Cancer Res 9:802-811.  
Bull H, Brickell P and Down P (1994) Src-related protein tyrosine kinases are 
phyosogically associated with the surface antigen CD36 in human dermal 
microvascular endothelial cells. FEBS lett 351:41-44. 
Burlacu A (2003) Regulation of apoptosis by bcl-2 family proteins. J Cell Mol 
Med 7: 249-257. 
 114 
 
Campbell L, Gubleton M and Griffiths D (2003) Caveolin-1 overexpression 
predicts poor disease-free survival of patients with clinically confined renal cell 
carcinoma. Br J Cancer 89:1909-1913. 
Campese V and Park J (2007) The kidney and hypertension:over 70 years of 
research. J Nephrol 19:691-698. 
Cardillo M, Lazzereschi D, Gansini O, Di Solverio F and Colleta G. (2001) 
Transforming growth factor-beta pathway in human renal cell carcinoma and 
surrounding normal-appearing renal parenchyma. Anal Quant Cytol Histol 
23:109-117. 
Carrion R, Morgan B, Tannenbaum M, Salup R and Morgan M (2003) Caveolin 
expression in adult renal tumors. Urol Oncol 21:191-196. 
Catzavelos C, Bhattacharya N, Ung Y, Wilson J, Roncari L, Sadnhu C, Shaw P, 
Yeger H, Morava-Protzner, Kaputsa L, Franssen E, Pritchard K, Slingerland J 
(1997) Decreased levels of the cell-cycle inhibitor p27/Kip1 protein: prognostic 
implications in primary breast cancer. Nat Med 3:227-230. 
Chang TH and Szabo E (2000) Induction of differentiation and apoptosis by 
ligands of peroxisome proliferator-activated receptor g in non-small cell lung 
cancer. Cancer Res 60:1129-38. 
Chintharlapalli S, Burghardt R, Papineni S, Ramaiah S, Yoon K and Safe S 
(2005a) Activation of Nur77 by selected 1,1-Bis(3'-indolyl)-1-(p-substituted 
phenyl)methanes induces apoptosis through nuclear pathways. J Biol Chem 
280:24903-24914. 
 115 
 
Chintharlapalli S, Papineni S, Baek SJ, Liu S and Safe S (2005b) 1,1-Bis(3'-
indolyl)-1-(p-substitutedphenyl)methanes are peroxisome proliferator-
activated receptor gamma agonists but decrease HCT-116 colon cancer cell 
survival through receptor-independent activation of early growth response-1 
and NAG-1. Mol Pharmacol 68:1782-92. 
Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S 
(2005c) 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related 
compounds inhibit growth of colon cancer cells through peroxisome 
proliferator-activated receptor g-dependent and -independent pathways. Mol 
Pharmacol 68:119-128. 
Chintharlapalli S, Papineni S and Safe S (2006) 1,1-Bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes inhibit colon cancer cell and tumor growth 
through PPARγ-dependent and PPARγ-independent pathways. Mol Cancer 
Ther 5:1362-1370. 
Chintharlapalli S, Papineni S, Safe S (2007) 1,1-Bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes inhibit growth, induce apoptosis, and decrease 
the androgen receptor in LNCaP prostate cancer cells through peroxisome 
proliferator-activated receptor gamma-independent pathways. Mol 
Pharmacol 71:558-569. 
Christiansen C, Christiansen M, Melson F, Rodbro P and Deluca H (1981) 
Mineral metabolism in chronic renal failure with special reference to serum 
concentrations of 1,25(OH)2D and 24,25(OH)2D. Clin Nephrol 15:18-22. 
 116 
 
Christoph F, Kempkensteffen C, Weikert S, Krause H, Schostak M, Schrader M 
and Miller K (2006) Methylation of tumor suppressor genes APAF-1 and 
DAPK-1 and in vitro effects of demethylating agents in bladder and kidney 
cancer. Br J Cancer 95: 1701-1707. 
Clevers H, Alarcon B, Wileman T and Terhorst C (1988) The T-cell receptor/CD3 
complex: a dynamic protein ensemble. Am Rev Immunol 6: 629-662. 
Cole S, Bhardwag G, Gerlach J, Mackie J, Grant C, Almquist K, Stewart A, Kurz 
E, Duncan A and Deeley R (1992) Overexpression of a transporter gene in a 
multidrug-resistant human lung cancer cell line. Science 258:1650-1654. 
Commandeur J, de Kanter F and Vermeulen N (1989) Bioactivation of cysteine-
S-conjugate and mercapturic acid of tetraflouroethylene to acylating reactive 
intermediates in the rat.  Dependence of activation and deactivation activities 
on acetyl coenzyme A availability. Mol Pharmacol 36: 654-663. 
Commandeur J and Vermeulen N (1990) Molecular and biochemical 
mechanisms of chemically induced nephrotoxicity: A Review. Chem Res 
Toxicol 3:171-189. 
Contractor R, Samudio I, Estrov Z, Harris D, McCubrey J, Safe S, Adreeff M, 
Konopleva M (2005) A novel ring-substituted diindolylmethane 1,1-bis[3'-(5-
methoxyindolyl)]-1-(p-t-butylphenyl)methane inhibits ERK activation and 
induces apoptosis in acute myeloid leukemia. Cancer Res 65:2890-2898. 
 117 
 
Cooper A, Bruschi S and Anders M (2002) Toxic, halogenated cysteine S-
conjugates and targeting of mitochondrial enzymes of energy metabolism. 
Biochem Pharmacol 64: 553-564. 
Copland J, Luxon B, Ajani L, Maity, Campagnaro E, Guo H, LeGrand S, Tamboli 
P and Wood C (2003) Genomic profiling identifies alterations in TGF-beta 
signaling through loss of TGF-beta recptor expression in human renal cell 
carcinogenesis and progression. Oncogene 22: 8053-8062. 
Cordon-Cardo C, and Prives C (1999) At the crossroads of inflammation and 
tumorigenesis. J Exp Med 190: 1367-1370. 
Coresh J, Byrd-Holt D, Astor B, Briggs J, Eggers P, Lacher D and Hostetter T 
(2005) Chronic kidney disease awareness, prevention, and trends in US 
adults, 1999 to 2000. J Am Soc Nephrol 16:180-188. 
Corton JC, Anderson SP and Stauber A (2000) Central role of peroxisome 
proliferator-activated receptors in the actions of peroxisome proliferators. 
Annu Rev Pharmacol Toxicol 40:491-518. 
Dang C and Semenza G (1999) Oncogenic alterations of metabolism. Trends in 
Biochem Sci. 24:68-72. 
Dekant W and Vamvakas S (1996) Biotransformation and membrane transport 
in nephrotoxicity. Crit Dev Toxicol 26:309-334. 
Dembic Z, Haas W, Weiss S, McCubrey J, Keifer H, von Beohmer H and 
Steinmetz M (1986) Transfer of specificity by murine alpha and beta T-cell 
receptor genes. Nature 320:232-238. 
 118 
 
de Paulsen N, Brychzy A, Fournier M, Kluasner R, Gnarra J, Pause A and Lee S 
(2001) Role of transforming growth factor-alpha in von-Hippel Lindau (VHL)(-/-
) clear cell renal carcinoma cell proliferation: a possible mechanism coupling 
VHL tumor suppressor inactivation and tumorigenesis. PNAS 98:1387-1392. 
Deryugina E and Quigley J (2006) Matrix metalloproteinases and tumor 
metastasis. Cancer Metastasis Rev 25:9-34.  
Desvergne B and Wahli W (1999) Peroxisome proliferator-activated receptors: 
nuclear control of metabolism. Endocr Rev 20:649-88. 
Dillon R, White D and Muller W (2007) The phosphatidyl inositol 3-kinase 
signaling network: implications for human breast cancer. Oncogene 26:1338-
1345. 
Dinour D, Chang M, Satoh J, Smith BL, Angle N, Knecht A, Serban I, Holtzman 
E and Romero M (2004) A novl missense mutation in the sodium bicarbonate 
cotransporter (NBCe1/SLC4A4) causes proximal tubular acidosis and 
glaucoma through ion transport defects. J Biol Chem 279:52238-52246.  
Dische F, Weston M and Parsons V (1985) Abnormally thin glomerular 
basement membranes associated with hematuria, proteinuria or renal failure 
in adults. Am J Nephrol 5:103-109. 
Doll R and Peto R (1981) the causes of cancer: quantitative estimates of 
avoidable risks of cancer in the US today. J Natl Cancer Inst 66:1191-1308. 
Dong D, Dubeau L, Bading J, Nguyen K, Luna M, Yu H and Gazit-Bornstein 
(2004) Spontaneous and controllable activation of suicide gene expression 
 119 
 
driven by the stress-inducible grp78 promoter resulting in eradication of 
sizable human tumors. Hum Gene Ther 15:553-561. 
Dunham M, Neumann A, Fasching C and Reddel R (2000) Telomere 
maintenance by recombination in human cells. Nat Genet 26: 447-450. 
Dunn G, Bruce A, Ikeda H, Old L and Schrieber R (2002) Cancer 
immunoediting: from immunosurveilance to tumor escape. Nat Immunol 
3:991-998. 
Duriez P and Shah G (1997) Cleavage of poly(ADP-ribose) polymerase: a 
sensitive parameter to study cell death. Biochem Cell Biol 75: 337-349. 
Dvorak H (2002) Vascular permeability factor/vascular endothelial growth factor: 
a critical cytokine in tumor angiogenesis and a potential target for diagnosis 
and therapy. J Clin Oncol 20:4368-4380. 
Dvorak H, Senger D, Dvorak A, Harvey V and McDonagh J (1985) Regulation of 
extravascular coagulation by microvascular permeabiltiy. Science 227:1059-
1061. 
Edgington T, Glassock R and Dixon F (1968) Autologous immune complex 
nephritis induced with renal tubular antigen. Identification and isolation of the 
pathogenetic antigen. J Exp Med 127:555-572. 
Eling T, Baek S, Shim M and Lee C (2006) NSAID activated gene (NAG-1), a 
modulator of tumorigenesis. J Biochem Mol Biol 39: 649-655. 
Elnemr A, Ohta T, Iwata K, Ninomia L, Fushida S, Nishimura G, Kitagawa H, 
Kayahara M, Yammoto M, Terada T and Miwa K (2000) PPARγ ligand 
 120 
 
(thiazolidinedione) induces growth arrest and differentiation markers of 
human pancreatic cancer cells. Int J Oncol 17:1157-1164.  
Elstner E, Muller C, Koshizuka K, Williamson E, Park D, Asou H, Shintaku P, 
Said J, Heber D, Koeffler H (1998) Ligands for peroxisome proliferator-
activated receptor gamma and retinoic acid receptor inhibit growth and 
induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc 
Natl Acad Sci U S A 95:8806-8811. 
Engelman J, Zang X, Galbiati F and Lisanti M (1999) Genes encoding human 
caveolin-1 and 2 are located to the D7S522 locus (7q31.1) a known fragile 
site that is frequently deleted in human cancers. FEBS Lett 436:403-410.  
Escher P and Wahli W (2000) Peroxisome proliferator-activated receptors: 
insight into multiple cellular functions. Mutat Res 448:121-138. 
Esteban M, Tran M, Harten S, Hill P, Castellanos M, Chandra A, Raval R, 
O’brien T, Maxwell P (2006) Regulation of E-daherin expression by VHL and 
Hypoxia-inducible factor. Cancer Res 66:3567-3575.  
Evans W and Relling M (1999) Pharmacogenomics: translating functional 
genomics into rational therapeutics. Science 286:487-491. 
Fajas L, Debril MB and Auwerx J (2001) Peroxisome proliferator-activated 
receptor-g: from adipogenesis to carcinogenesis. J Mol Endocrinol 27:1-9. 
Fan Y, Liu Z, Fang X, Ge Z, Ge N, Jia Y, Sun O, Lou F, Bjorkholm M, Gruber A, 
Ekman P and Xu D (2005) Differential expression of full-length reverse 
 121 
 
transcriptase mRNA and telomerase activity between normal and malignant 
renal tissues. Clin Cancer Res 11:4331-4337. 
Farber J and el Mofty S (1975) The biochemical pathology of liver cell necrosis. 
Am J Pathol 81:237-250. 
Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Eng J Med 
285:1182-1186.  
Fujiwara T, Verbalis, J and Nielson S (1995) Molecular biology of diabetes 
insipidus. Annu Rev Med 46:331-343. 
Gazit G, Lu J and Lee A (1999) De-regulation of GRP stress protein expression 
in human breast cancer cell lines. Breast Cancer Res Treat 54:135-146. 
Giancotti F and Ruoshlahti E (1999) Integrin signaling. Science 285:1028-1032. 
Giehl K (2005) Ocogenic Ras in tumour progression and metastasis. Biol Cheml 
386:193-205.  
Grommes C, Landreth G and Heneka M (2004) Antineoplastic effects of 
Peroxisome proliferator-activated receptor y agonists. Lancet Oncol 5:419-
429. 
Griffith J, Comeau L, Rosenfield S, Stansel R, Bianchi A, Moss H and de Lange 
T (1999) Mammalian telomeres end in a large duplex loop. Cell 97:503-514. 
Gudjonsson T and Magnusson M (2005) Stem cell biology and the cellular 
pathways of carcinogenesis. APMIS 113:922-929. 
 122 
 
Gudjonsson T, Villadsen R, Nielson H, Ronnov-Jessen L, Bissel M and Peterson 
O (2002) Isolation, immortalization and characterization of a human breast 
epithelial cell line with stem cell properties. Genes Dev 16:693-706. 
Gupta RA, Brockman JA, Sarraf P, Willson TM and DuBois RN (2001). Target 
genes of peroxisome proliferator-activated receptor g in colorectal cancer 
cells. J Biol Chem 276:29681-2967. 
Gupta RA, Sarraf P, Mueller E, Brockman J, Prusakiewicz J, Eng C, Wilson T 
and DuBois R (2003) Peroxisome proliferator-activated receptor g-mediated 
differentiation: a mutation in colon cancer cells reveals divergent and cell 
type-specific mechanisms. J Biol Chem 278:22669-22677. 
Gurova K, Hill J, Razorenova O, Chumakov P and Gudkov A (2004) p53 
pathway in Renal cell carcinoma is repressed by a dominant mechanism. 
Cancer Res 64:1951-1958. 
Hai T and Hartman M (2001) The molecular biology and nomenclature of the 
activating transcription factor/cAMP responsive element binding family of 
transcription factors: activating transcription factor proteins and homeostasts. 
Gene 273:1-11. 
Hanahan D and Weinberg R (2000) The hallmarks of cancer. Cell 100:57-70. 
Harris C (1996) p53 tumor suppressor gene: from the basic research laboratory 
to the clinic- an abridged historical perspective. Carcinogenesis 17:1187-
1198. 
 123 
 
Hart I and Fidler I (1980) Role of organ selectivity in the determination of 
metastatic patterns of B16 melanoma. Cancer Res 40:2281-2287.  
Hayflick L (1964) The limited in vitro lifetime of human diploid cell strains. Exp 
Cell Res 37:614-636. 
Hecht S, Carmela S, Mori H and Hoffman D (1981) A study of tobacco 
carcinogenesis XX. Role of catechol as a major cocarcinogen in the weakly 
acidic fraction of smoke condensate. J Natl Cancer Inst 66:163-169. 
Hedberg Y, Ljungberg B, Roos G and Landberg G (2004) Retinoblastoma 
protein in human renal cell carcinoma in relation to alterations in G1/S 
regulatory protiens. Int J Cancer 109:189-193. 
Hegele A, Varga Z, von Knobloch, Heidenreich A. Olbert P, Kropf J, Hofmann R 
(2003) Cellular fibronectin in patients with transitional cell carcinoma of the 
bladder. Urol Res 301:126-129. 
Hemminki K and Xinjun L (2002) Cancer risks in second-generation immigrants 
to Sweden. Int J Cancer 99:229-237. 
Herrera M, Ortiz P and Garvin J (2006) Regulation of the thick ascending limb 
transport: role of nitric oxide. Am J Physiol Renal Physiol 290:F1279-F1284. 
Hoenderop J, Nilius B and Bindels R (2005) Calcium absorption across epithelia. 
Physiol Rev 85:373-422. 
Holick M (2003) Vitamin D: a millinium perspective. J Cell Biochem 62:301-313. 
 124 
 
Holick M (2004) Sunlight and vitamin D for bone health and prevention of 
autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 
80:1678S-1688S. 
Holmberg C, Antikainen M, Ronnholm K, Ala-Louhala M and Jalenko H (1995) 
Management of congenital nephritic syndrom of the Finnish type. Pediatr 
Nephrol 9:87-93. 
Hong J, Samudio I, Liu S, Abdelrahim M and Safe S (2004) Peroxisome 
proliferator-activated receptor g-dependent activation of p21 in Panc-28 
pancreatic cancer cells involves Sp1 and Sp4 proteins. Endocrinology 
145:5774-5785. 
Hunt J, van der Hel, O, McMilliam G, Boffeta P and Brennan P (2005) Renal cell 
carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J 
Cancer 114:101-108. 
Hursting S, Slaga T, Fishcer S, DiGiovanni J, Phang J (1999) Mechanism-based 
cancer prevention approaches: targets, examples, and the use of transgenic 
mice. J Natl Cancer Inst 91:215-225. 
Ikezoe T, Miller CW,  Kawano S, Heaney A, Williamson F, Histake J, Green E, 
Hofmann W, Taguchi H and Koeffler H (2001) Mutational analysis of the 
peroxisome proliferator-activated receptor g gene in human malignancies. 
Cancer Res 61:5307-5310. 
Inui K, Satohiro M and Saito H (2000) Cellular and molecular aspects of drug 
transport in the kidney Kidney Int 58:944-958.  
 125 
 
Isseman I and Green S (1990) Activation of a member of the steroid hormone 
receptor superfamily by peroxisome proliferators. Nature 347:645-650.  
Jalanko H, Patrakka J, Tryggvason K and Holmberg C (2001) Genetic kidney 
diseases disclose the pathogenesis of proteinusia. Ann Med 33:526-533.  
Jaradat M and Molitoris B (2002) Cardiovascular disease in patients with chronic 
kidney disease. Sem Nephrol 59:615-627.  
Jemal A, Siegal R, Ward E, Murray T, Xu J, Smigal C and Thun M (2006) Cancer 
Statistics, 2006. CA Cancer J Clin. 56:106-130.  
Kalluri R, Shield C, Todd P, Hudson B and Neilson E (1997) Isoform switching of 
type IV collagen is developmentally arrested in X-linked Alport syndrome 
leading to increased susceptibility of renal basement membranes to 
endoproteolysis. J Clin Invest 98:2470-2478. 
Kanwar Y (1984) Biology of disease: biophysiology of glomerular filtration and 
proteinuria. Lab Invest 51:7-21.  
Karlsseder J, Smogorzesska A, de Lange T (2002) Senescence induced by 
altered telomere state, not telomere loss. Science 295:2446-2449.  
Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S and Kamat A. 
(2006) Inhibition of bladder tumor growth by 1,1-Bis(3'-indolyl)-1-(p-
substitutedphenyl)methanes: a new class of peroxisome proliferator-
activated receptor gamma agonists. Cancer Res 66:412-418. 
Kato M, Kusumi T, Tsuchida S, Tanaka M, Sasaki M and Kudo H (2004) 
Induction of differentiation and peroxisome proliferator-activated receptor g 
 126 
 
expression in colon cancer cell lines by troglitazone. J Cancer Res Clin Oncol 
130:73-79. 
Kestila M, Lenkkeri U, Mannikko M, Lamerdin J, McCready P, Putaala H, 
Ruotsalainen V, Morita T, Nissinen M, Herva R, Kashtan C, Peltnonen L, 
Holmberg C, Olsen A and Tryggvason K (1998) Positionally cloned gene for a 
novel glomerular protein-nephrin is mutated in congenital nephritic syndrome. 
Mol Cell 1:575-582.  
Khosla S (2001) The OPG/RANKL/RANK system. Endocrinology 142:5050-
5055.  
Kim J, Tchernshyov, Semenza G and Dang C (2006) HIF-1-mediated 
expression of pyruvate dehydrogenase kinase: A metabolic switch required 
for cellular adaptation to hypoxia. Cell Metabol 3:177-185.  
Kimura K, Hirata T, Nanba S, Tojo A, Matuoka H and Sugimoto T (1990) Effects 
of atrial natriuretic peptide on renal arterioles: morphometric analysis using 
microvascular casts. Am J Physiol 259:F936-944.  
Kinne R (1975) Polarity of the proximal tubular cell: function and enzyme pattern 
of the isolated plasma membranes. Med Clin North Am 59:615-627.  
Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S and Matsuzawa Y 
(1999). Peroxisome proliferator-activated receptor g induces growth arrest 
and differentiation markers of human colon cancer cells. Jpn J Cancer Res 
90:75-80. 
 127 
 
Knepper M and Inoue T (1997) Regulation of aquaporin-2 water channel 
trafficking by vasopressin. Curr Opin Cell Biol 9:560-564.  
Knight D and Stadler W (2007) Prognostic factors in localized renal cell cancer. 
BJU Int 99:1212-1216.  
Koide A, Fuwa K, Furukawa F, Hirose M, Nishikawa A and Mori Y (1999) Effect 
of cigarette smoke on the mutagenic activation of environmental carcinogens 
by rodent liver. Mutat Res 428:165-176.  
Koong A, Chen E, Lee A, Brown J and Giaccia A (1994) Increased cytotoxicity of 
chronic hypoxic cells by molecular inhibition of GRP78 induction. Int J Radiat 
Oncol Biol Phys 1:661-616.  
Kopper L and Timar J (2006) Genomics of renal cell cancer-does it provide 
breakthrough. Pathol Oncol Res 12:5-11.  
Koumenis C (2006) ER stress, hypoxia tolerance and tumor progression. Curr 
Mol Med 6:55-69.  
Kubic V and Anders M (1978) Metabolism of dihalomethanes to carbon 
monoxide-III. Studies in the mechanism of the reaction. Biochem Pharmacol 
27:2349-2355. 
Lash L and Anders M (1989) Uptake of nephrotoxic S-conjugates by isolated rat 
renal proximal tubular cells. J Pharmacol Exp Ther. 248:531-537. 
Lee CH, Olson P and Evans RM (2003) Minireview: lipid metabolism, metabolic 
diseases, and peroxisome proliferator-activated receptors. Endocrinology 
144:2201-2207. 
 128 
 
Lee S, Yamaguchi K, Kim J, Eling T, Safe S, Park Y and Baek S (2006) 
Conjugated linoleic acid stimulates an anti-tumorgenic protein NAG-1 in an 
isomer specific manner. Carcinogenesis 27:972-981. 
Lei P, Abdelrahim M and Safe S (2006) 1,1-Bis(3'-indolyl)-1-(p-substituted 
phenyl)methanes inhibit ovarian cancer cell growth through peroxisome 
proliferator-activated receptor-dependent and independent pathways. Mol 
Cancer Ther 5:2324-2336. 
Lemmink H, Schroder C, Monnens L and Smeets H (1997) The clinical spectrum 
of type IV collagen mutations. Hum Mutat 9:477-499. 
Leung S and Ohh M (2002) Playing tag with HIF: the VHL story. J Biomed 
Biotechnol 2:131-135. 
Levin A (2006) Kidneys, hearts, hormones and immunomodulators: integrated 
understandings. Blood Purif 24:46-50.  
Li B, Gao B, ye L, Han X, Wang W, Kong L, Fang X, Zheng H, Li S, Wu Z, Ye L 
(2007) Adaptation to ER stress is mediated by differential stabilities of pro-
survival and pro-apoptotic mRNAs and proteins. PLoS Biol 4:e374.  
Li J and Lee A (2006) Stress induction of GRP78/BiP and its role in cancer. Curr 
Mol Med 6:5987-5993.  
Lin X, Nelson PP, Gelman H (2000) SSeCKS, a makor protein kianse C 
substrate with tumor suppressor activity, regulates G1-S 
compartmentalization of cyclin D. Mol Cell Bioll 18:7259-7272. 
 129 
 
Li P, Wong J, Ayed A, Ngo D, Brade A, Arrowsmith C, Austin R and Klamut H 
(2000) Placental transforming growth factor-beta is a downstream mediator of 
the growth arrest and apoptotic response of tumor cells to DNA damage and 
p53 overexpression. J Biol Chem 275:20127-20135. 
Lipworth L, Tarone R and McLaughlin J (2006) The epidemiology of renal cell 
carcinoma. J Urol 176:2353-2358.  
Liotta L, Kleinerman J and Saidel G (1974) Quantitative relationships of 
intravascular tumor cells: tumor vessels and pulmonary metastases following 
tumor implantation. Cancer Res 34:997-1003.  
Liu X, Zou H, Slaughter C and Wang X (1997) DFF, a heterodimeric protein that 
functions downstream of caspase-3 to trigger DNA fragmentation during 
apoptosis. Cell 89:175-184. 
Loda M, Cukor B, Tam S, Lavin P, Fiorentino M, Draetta G, Jessup J, Pagano M 
(1997) Increased proteasome-dependent degredation of the cyclin-dependent 
kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:231-234.  
Lola P and Graham C (1990) Mechanisms of trophoblast invasiveness and their 
control: the role of the proteases and protease inhibitors. Cancer Metastasis 
Rev 9:396-380.  
Macklin K, Maus A, Pererira E, Albuquerque B, Conti-Fine B (1998) Human 
vascular endothelial cells express functional nicotinic acetylcholine receptors. 
J Pharmaco Exp Ther 287:435-439. 
 130 
 
Malabanan A, Turner A and Holick M (1998) Severe generalized bone pain and 
osteoporosis in premenopausal black female: effect of vitamin D replacement. 
J Clin Densitometr 1:201-204. 
Malumbres M and Barbacid M (2001) To cycle or not to cycle: a critical decision 
in cancer. Nat Rev Cancer 1:222-231. 
Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, 
Blumberg B, Kastner P, Mark M, Chambon P and Evans R (1995) The 
nuclear receptor superfamily:  the second decade. Cell 83:835-839. 
Mannervik B and Danielson U (1988) Glutathione transferases – structure and 
catalytic activity. Crit Rev. Biochem 283:283-337. 
Marin E and Sessa W (2007) Role of endothelial-derived nitric oxide synthase in 
hypertension and renal disease. Curr Opin Nephrol Hypertens 16:105-110.  
Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R, 
Zborowska E, Kinzler K, Vogelstein et al. (1995) Inactivation of the type II 
TGF-beta receptor in colon cancer cells with microsatellite instability. Science 
268:1336-1338. 
Mariotto A, Rowland J, Ries L, Scoppa S and Fauer E (2007) Multiple cancer 
prevalence: a growing challenge in long-term survivorship. Cancer Epidemiol 
Biomarkers Prev 16:566-571. 
Mashima T, Najito M, Fujita N, Noguchi K and Tsurou T (1995) Identification of 
actin as a substrate of ICE and an ICE-like protease and involvement of an 
 131 
 
ICE-like protease but not ICE in VP-16-induced U937 apoptosis. Biochem 
Biophys Res Commun 217:1185-1192. 
Mathew A, Devesa S, Fraumeni J and Chow A (2002) Global increases in 
kidney cancer incidence. 1973-1992. Eur J Cancer Prev 11:171-178. 
Maustakas A, Souchelnytksi S and Heldin C (2001) Smad regulation in TGF-
beta signal transduction. J Cell Sci 114:4359-4369. 
McCredie M, Pommer W, McLaughlin J, Stewart J, Lindblad P and Mandel J 
(1995) International renal cell cancer study II. Analgesics. Int J Cancer 
60:345-349. 
McDermott D and Rini B (2007) Immunotherapy for metastatic renal cell 
carcinoma. BJU Int 99:1282-1288.  
McLaughlin J and Lipworth L (2000) Epidemiologic aspects of renal cell cancer. 
Semin Oncol 27:115-123. 
McLaughlin J, Lindblad P, Mellemgaard A, McCredie M, Mandel, Schlehofer B, 
Pommer W and Adami H (1995) International renal-cell cancer study. I. 
Tobacco use. Int J Cancer 60:194-198. 
Medema R and Bos J (1993) The role of p21-ras in receptor tyrosine kinase 
signaling. Crit Rev Oncog 4:254-256.  
Melendez-Colon V, Luch A, Seidel A and Bair W (1999) Cancer initiation by 
polycyclic aromatic hydrocarbons results from formation of stable DNA 
adducts rather than apurinic sites. Carcinogenesis 20:1885-1891. 
 132 
 
Michael A and Pandha H (2003) Renal-cell carcinoma: tumour markers, T-cell 
epitopes, and potential for new therapies. Lancet Oncol 4:215-223.  
Miller D (1995) Daunomycin secretion by killifish renal proximal tubules. Am J 
Physiol 269:R370-R379. 
Mita M, Mita A and Rowinsky E (2003) The molecular target of rapamycin 
(mTOR) as a therapeutic target against cancer. Cancer Biol Ther 24:S169-
177.  
Moller DE (2001) New drug targets for type 2 diabetes and the metabolic 
syndrome. Nature 414:821-827. 
Monks T, Anders M, Dekant W, Stevens J, Lau S and van Bladeren P (1990) 
Glutathione conjugate mediated toxicities. Toxicol Appl Pharmacol 106:1-19. 
Morrison R and Farmer S (1999) Role of PPARgamma in regulating a cascade 
expression of cyclin-dependent kinase inhibitors, p18(INK4c) and 
p21(Waf1/Cip1), during adipogenesis. J Biol Chem 274:17088-17097.  
Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y (2000) Activation 
of peroxisome proliferator-activated receptor gamma by troglitazone inhibits 
cell growth through the increase of p27KiP1 in human pancreatic carcinoma 
cells. Cancer Res 60:5558-5564. 
Motzer RJ and Bukowski RM (2006) Targeted therapy for metastatic renal cell 
carcinoma. J Clin Oncol 2:5601-5608. 
Moustakas A, Souchelnytksyi S and Heldin C (2001) Smad regulationin TGF-
beta signal transduction. J Cell Sci 114:4359-4359. 
 133 
 
Mukhopadhyay D, Knebelmann B, Cohen H, Ananth S and Sukhatme V (1997) 
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to 
repress vascular endothelial growth promoter activity. Mol Cell Biol 17:5629-
5639. 
Nagata S (1997) Apoptosis by death factor. Cell 88:355-365. 
Nagi A, Alexander F and Barabas A (1971) Gold nephropathy in rats-light and 
electron microscope studies. Exp Mol Pathol 15:354-362. 
Nakamura S (2004) Glucose activates H(+)-ATPase in kidney epithelial cells. 
Am J Physiol Cell Physiol 287:C97-C105. 
Nangaku M and Couser W (2005) Mechanisms of immune-deposit formation 
and the mediation of immune renal injury. Clin Ex Neprol 9:183-191. 
Nash K, Hafeez A and Hou S (2002) Hospital aquired renal insufficiency. Am J 
Kidney Dis 39:930-936. 
Nebert D and Dalton T (2006) The role of cytochrome p450 enzymes in 
endogenous signaling pathways and environmental carcinogenesis. Nat Rev 
Cancer 6:947-960. 
Newman S, Sakaue M, Koo J, Kim K, Baek S, Eling T and Jetten A (2003) 
Differential regulation of nonsteroidal anti-inflammatory drug-activated gene in 
normal human tracheobronchial epitheial and lung carcinoma cells by 
retinoids. Mol Pharmacol 63:557-564. 
Nicholson D and Thornberry N (1997) Caspases: killer proteases. Trends 
Biochem Sci 22: 1312-1316. 
 134 
 
Novick A and Campbell S (2002) Campbells Urology (Walsh P, Retik AB, and 
Vaughan E, eds) pp 2672-2731, W.B. Saunders, Philadelphia. 
Nykjaer A, Dragun D, Wlather D, Vorum H, Jacobsen C, Herz J, Meslson F, 
Christensen E and Willnow T (1999) An endocytic pathway essential for renal 
uptake and activation of the steroid 25-(OH) vitamin D3. Cell 96:507-515 
O’Conner P (2006) Renal Oxygen Delivery: Matching delivery to metabolic 
demand. Clin Exp Pharmacol Physiol 33:961-967.  
Olovnikov A (1973) A theory of marginotomy.  The incomplete copying of 
template margin in enzymic synthesis of polynucleotides and biological 
significance of the phenominon. J Theor Biol 41:181-190. 
Oyadomari S and Mori M (2004) Roles of CHOP/GADD153 in endoplasmic 
reticulum stress. Cell Death Differ 11:381-389.  
Palmer C, Hsu M, Griffin H, Johnson E (1995) Novel sequence determinants in 
peroxisome proliferator signaling. J Biol Chem 270:16114-16121. 
Panigrahy D, Singer S, Shen L, Butterfield C, Freedman D, Chan E, Moses M, 
Kilroy S, Duensing S, Fletcher C, Fletcher J, Hlatky L, Hahnfeldt P, Folkman 
J and Kaipainen A (1999) PPARγ ligands inhibit primary-tumor growth and 
metastisis by inhibiting angiogenesis. J Clin Invest 110: 923-932. 
Paralkar V, Vail A, Grassner W, Brown T, Xu H, Vukicevic S, Ke H, Qi H, Owen 
T, Thompon D (1998) Cloning and characterization of a novel member of the 
transforming growth factor-beta/bone morphogenetic protein family. J Biol 
Chem 273:13760-13767. 
 135 
 
Pardee A (1974) A restriction point for control of normal cell proliferation. Proc 
Natl Acad Sci USA 71:1286-1290.  
Parhami F, Bostrom K, Watson K and Demer L (1996) Role of molecular 
regulation in vascular calcification. J Atheroscler Thromb 3:90-94.  
Petrella B and Brinckerhoff C (2006) Tumor cell invasion of von-Hippel Lindau 
renal cell carcinoma cells is mediated by membrane type-1 matrix 
metalloproteinase. Mol Cancer 5:66.  
Pilot H (1989) Progression: the terminal stage in carcinogenesis. Jpn J Cancer 
Res 80:599-607.  
Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble G, 
Lessnitzer L, Stimmel J, Wilson T, Rosen E and Spom M (2003) The novel 
synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and 
tumor growth in vivo. Clin Cancer Res 9:2798-2806. 
Portale A, Booth B, Halloran B and Morris R (1984) Effect of dietary phosphorus 
on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive 
parathyroid hormone in children with moderate renal insufficiency. J Clin 
Invest 73:1580-1589.  
Presta L, Chen H, O’Conner S, Chisholm V, Men Y, Krummen L, Winkler M and 
Ferrera N (1997) Humanization of an anti-vascular endothelial growth factor 
monoclonal antibody for the therapy of solid tumors and other disorders. 
Cancer Res 57:4593-4599.  
 136 
 
Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R and Rusnati M (2005) 
Fibroblast growth factor/fibroblast growth factor receptor system in 
angiogenesis. Cytokine Growth Factor Rev 29:305-317.  
Qin C, Burghardt R, Smith R, Wormke M, Stewart J, Safe S (2003) Peroxisome 
proliferator-activated receptor g (PPARg) agonists induce proteasome-
dependent degradation of cyclin D1 and estrogen receptor a in MCF-7 breast 
cancer cells. Cancer Res 63:958-964. 
Qin C, Morrow D,  Stewart J, Spencer K, Porter W, Smith R, Phillips T, 
Abdelrahim M, Samudio L and Safe S (2004). A new class of peroxisome 
proliferator-activated receptor g (PPARg) agonists that inhibit growth of 
breast cancer cells:  1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes. Mol 
Cancer Therap. 3:247-59. 
Rahn K, Heidenreich S and Bruckner D (1999) How to assess glomerular 
function and damage in humans. J. Hypertens 17:309-317.  
Rashidkhani B, Lindblad P and Wolk A (2005) Fruits, vegetables and risk of 
renal cell carcinomas: a prospective study of Swedish women. Int J Cancer 
113:451-455.  
Razani M, Woodman S and Lisanti M (2002) Caveolae: from cell biology to 
animal physiology. Pharmacol Rev 54:431-467.  
Renan M (1993) How many mutations are required for tumorigenesis?  
Implications from human cancer data. Mol Carcinogenesis 7:139-146.  
 137 
 
Reitz R, Medrala A and Guengerich F (1989) In vitro metabolism of methylene 
chloride in human and animal tissue: use in physiologically based 
pharmacokinetic models. Toxicol Appl Pharmacol 97:230-246. 
Rini B and Rathmell K (2007) Biological Aspects and Binding strategies of 
vascular endothelial growth factor in renal cell carcinoma. Clin Cancer Res 
13(suppl): 741S-764S. 
Robertson G (1983) Thirst and vasopressin function in normal and disorders 
states of water balance. J Lab Clin Med 101:35-371.  
Robertson E and Rankin G (2006) Human renal organic anion transporters: 
characteristics and contributions to drug and drug metabolite excretion. 
Pharm Ther 109:399-412.  
Roe J, Kim H, Lee S, Kim S, Cho E and Youn H (2006) p53 stabilization and 
transactivation by a von-Hippel-Lindau protein. Mol Cell 22:385-405. 
Rosenberg S, Mule J, Spiess P, Reichert C and Schwarz S (1985) Regression 
of established pulmonary metastases and subcutaneous tumor mediated by 
the systemic administration of high dose recombinant interleukin 2. J Exp 
Med 161: 1169-1188. 
Rosen E and Spiegelman BM (2001) PPARg:  a nuclear regulator of 
metabolism, differentiation, and cell growth. J Biol Chem 276:37731-37334. 
Rubin H (2002) Selective clonal expansion and microenvironmental 
permissiveness in tobacco carcinogenesis. Oncogene 21:7392-7411.  
 138 
 
Ruggeri B, DiRado M, Zhang S, Bauer B, Goodrow T and Klein-Szanto A (1993) 
Benzo[a]pyrene-induced murine skin tumors exhibit frequent and 
characteristic G to T mutations in the p53 gene. Proc Natl Acad Sci USA 
90:1013-1017.  
Ruth J and Wassner S (2006) Body composition: salt and water. Pediatr Rev 
27:181-187.  
Sabo E, Miselevich I, Bejar J, Segenreich M, Wald M, Moskovitz B and Nativ O 
(1997) The role of vimentin expression in predicting the long-term outcome of 
patients with localized renal cell carcinoma. Br J Urol 80: 864-868.  
Sainsbury J, Anderson T and Morgan D (2000) ABC of breast disease: breast 
cancer. BMJ 321:745-750.  
Sakahira H, Enari M and Nagata S (1998) Cleavage of CAD inhibitor in CAD 
activation and DNA degredation during apoptosis. Cell 89: 96-99. 
Sano F, Elisabetta F, Tufi R, Achsel T, Piacentini M and Cecconi F (2006)  
Endoplasmic reticulum stress induced apoptosis by an apoptososme-
dependent but caspase 12-independent mechanism. J Biol Chem 281: 2693-
2700. 
Sarnak M and Levey A (2000) Epidemiology, diagnosis, and management of 
cardiac disease in chronic renal disease J Thromb Thrombolysis 10:169-180.  
Schaller m, Hildebrand J, Shannon J, Fox J, Vines R and Parsons J (1994) 
Autophosphorylation of the focal adhesion kinase pp125FAK, direscts SH2-
dependent binding of pp60src Mol Cell Bio 14:1660-1668.  
 139 
 
Schlaepfer D, Hanks S, Hunter T and van der Geer P (1994) Integrin-mediated 
signal transduction linked to Ras pathway by Grb2 binding to focal adhesion 
kinase. Nature 372:786-791.  
Sejima T, Isoyama T, Miyagawa I (2003) Alteration of apoptotic regulatory 
molecules expression during carcinogenesis and tumor progression of renal 
cell carcinoma. Int J Urol 10:476-484.  
Sell S (2004) Stem cell origin of cancer and differentiation therapy. Crit Rev 
Oncol Hematol 51:1-28.  
Senger D, Galli S, Dvorak A, Perruzzi C, Harvey V and Dvorak H (1997) Tumor 
cells secrete a vascular permeability factor that promotes accumulation of 
ascites fluid. Science 219:983-985.  
Shack S, Wang X, Kokkonen G, Gorospe M, Longo D and Holbrook N (2003) 
Caveolin-induced activation of phophatidylinositol 3-kinase/Akt pathway 
increases arsenite cytotoxicity. Moll Cell Bio 23:2407-2414.  
Shay J and Wright W (2005a) Senescence and immortalization: role of 
telomeres and telomerase. Carcinogenesis 26:867-874. 
Shay J, Wright W and Werbin H (1991) Defining the molecular mechanisms of 
human cell immortalization. Biochim Biophys Acta 1072:1-7. 
Smith K and Gunaratnum et al. (2005) Silencing of epidermal growth factor 
receptor suppresses hypoxia-inducible factor-2 driven VHL -/- renal cancer. 
Cancer Res 65:5221-5230 
Sporn M (1996) War on cancer. Lancet 347:1377-1381.  
 140 
 
Stanton B and Koeppen B (2001) Renal Physiology 3rd edition. Mosby, Missouri. 
Starry H (2000) Natural history of calcium deposits in the atherosclerosis 
progression and regression. Z Kardiol 89:28-35. 
Staeler M, Rohrmann N, Haseke C, Stief C and Siebels M (2005) Targeted 
agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 
6: 835-846.  
Stevens J and Jakoby W (1983) Cysteine conjugate β-lysase. Mol Pharmacol 
23:761-765. 
Stewart A and Weinberg R (2006) Telomeres: cancer to human aging. Annu rev 
Cell Dev Biol 22:531-557. 
Strand S, Hoffman W and Hug H et al. (1996) Lymphocyte apoptosis induced by 
CD95 (APO-1/Fas) ligand-expressing tumour cells: a mechanism of immune 
evasion. Nature Med 2: 1361-1366. 
Suki W (1979) Calcium transport in the nephron. Am J Physiol 237:F1-F6.  
Suzuki Y, Ruiz Ortega M, Gomez-Guerrero C, Tomino Y and Egido J (2003) 
Angiotensin II, the immune system and renal diseases, another road for RAS? 
Nephrol Dial Transplant 18:1423-1426. 
Swanton C (2004) Cell-cycle targeted therapies. Lancet Oncol 5:27-36. 
Sweeney C and Farrow D (2000) Differential survival related to smoking among 
patients with renal cell carcinoma Epidemiology 11:344-346. 
Tahir S, Yang G, Ebara S, Timme T, Satoh T, Li L, Goltsoc A, Itmann M, 
Morrisett J, Thompson T (2001) Secreted caveolin-1 stimulates cell 
 141 
 
survival/clonal growth and contributes to metastasis in androgen-insensitive 
prostate cancer. Cancer Res 61:3882-3885.  
Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I and Kohgo Y 
(1999) Activation of PPARg inhibits cell growth and induces apoptosis in 
human gastric cancer cells. FEBS Lett 455:135-9. 
Takamoto S, Onishi T, Morimoto S, Imanaka S, Tsuchiya S, Seino Y, Yokokawa 
T, Iida N and Kumahara Y (1985) Serum phosphate, parathyroid hormone 
and vitamin D metabolites in patients with chronic renal failure: effect of 
aluminum hydroxide administration. Nephron 40:286-291.  
Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J and Kato S (1997) 
25-hydroxyvitamin D3, 1α-hydroxylase and vitamin D synthesis. Science 
277:1827-1830.  
Talhouk R, Bisell M and Werb Z (1992) Coordinated expression of extracellular 
matrix proteinases and their inhibitors regulates mammary epithelial function 
during involution. J Cell Biol 118:1271-1282.  
Tareen N, Martins D, Nagami G, Levine B and Norris K (2005) Sodium disorders 
in the elderly. J Natl Med Assoc 97:217-224.  
Thompson C, Bland J, Burd J and Baylis P (1986) The osmotic thresholds for 
thirst and vasopressin release are similar in healthy man. Clin Sci 71:651-656.  
Tomita Y (2006) Early renal cell cancer. Int J Clin Oncol 11:22-27. 
 142 
 
Trachtman H (1991) Cell volume regulation: a review of cerebral adaptive 
mechanisms and implications for clinical treatment of osmolal disturbances. 
Pediatr Nephrol 5:743-750.  
Tsui K, Shvarts O, Smith R, Figlin R, deKernion J and Belledegrun A (2000) 
Renal cell carcinoma prognostic significance of incidentally detected tumors. 
J Urol 163:426-430.  
Uwai Y, Okuda M, Takami K, Hashimoto Y and Inui K (1998) Functional 
characterization of the rat multispecific organic anion transporter OAT1 
mediating basolateral uptake of anionic drugs in the kidney. FEBS letters 
438:321-324. 
Van Duuren B and Goldschmidt B (1976) Cocarcinogenic and tumor-promoting 
agents in tobacco carcinogenesis. J Natl Cancer Inst 56:1237-1242.  
Verbalis J (2003) Disorders of body water homeostasis. Best Pract Res Clin 
Endocrinol Metab 17:471-503.  
Vermeulen K, Bockstacle D and Berneman Z (2005) Apoptosis: mechanisms 
and relevance in cancer. Ann Hematol 84:627-639. 
Virtanen I and Lehto V (2004) Progression of malignancy in clear cell renal cell 
carcinomas. Scand J Surg 93:112-117. 
Vogelzang N and Sternberg C (2007) Signal-transduction inhibitors in renal cell 
carcinoma. BJU Int 99:1289-1295.  
Volkel W and Dekant W (1998) Chlorothioketene, the ultimate reactive 
intermediate formed by cysteine conjugate beta-lyase-mediated cleavage of 
 143 
 
the trichloroethene metabolite S-(1,2-Dichlorovinyl)-L-cysteine, forms cytosine 
adducts in organic solvents, but not in aqueous solution. Chem Res Toxicol 
11:1082-1088. 
Volpe A and Jewett M. (2005) The natural history of small renal masses. Nat 
Clin Pract Urol 2: 384-390. 
Wagner A, Kovacikova J, Stehberger P, Winter C, Banabbas C and Mohebbi N 
(2006) Renal acid-base transport: old and new players. Nephron Physiol 
103:1-6.  
Watson J (1974) Origin of concatemeric T7 DNA. Nat New Biol 239:197-201. 
Weinberg R, Masson S and Grose A (2007) The biology of cancer. Garland 
Science, Taylor and Francis group, New York. 
Weinstein I (1988) The origins of human cancer: molecular mechanisms of 
carcinogenesis and their implications for cancer prevention and treatment-
twenty-seventh G.H.A. Clowes memorial award lecture. Cancer Res 48:4135-
4143.  
Wheeler J, Stourman N, Their R, Dommermouth A, Vuilleumier S, Rose, 
Armstrong R, Guengerich F (2002) Conjugation of haloalkanes by bacterial 
and mammalian glutathione transferases: mono- and dihalomethances. Chem 
Res Toxicol 14:1118-1127. 
Williams R (1971) The metabolism of certain drugs and food chemicals in man. 
Ann N Y Acad Sci 179:141-154. 
 144 
 
Williams TM, Hassan GS, Li J, Cohen A, Medina F, Frank P, Pestell R, Di Vizio 
D, Loda M and Lisanti M (2005) Caveolin-1 promotes tumor progression in an 
autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 
delays advanced prostate tumor development in tramp mice. J Biol Chem 
280:25134-25145. 
Willson TM, Brown PJ, Sternbach DD and Henke BR (2000) The PPARs: from 
orphan receptors to drug discovery. J Med Chem 43:527-50. 
Willson TM, Lambert MH and Kliewer SA (2001) Peroxisome proliferator-
activated receptor g and metabolic disease. Annu Rev Biochem 70:341-67. 
Woodhouse E, Chuaqui R and Liotta L (1997) General mechanisms of 
metastasis. Cancer 80:1529-1537.  
Wotkowicz C and Libertino J (2007) Renal cell cancer: radical nephrectomy. 
BJU 99:1231-1238. 
Wright S (2005) Role of organic cation transporters in the renal handling of 
therapeutic agents and therapeutics. Toxicol Appl Pharmacol 204:309-319.  
Wright S, Zhong J and Larrick J (1994) Inhibition of apoptosis as a mechanism 
of tumor promotion. FASEB J 8:654-660.  
Yang G, Truong L, Timme T, Ren C, Wheeler T, Park S, Nasu Y, Bangma C, 
Katan M, Scardino P, Thompson T (1998) Elevated expression of caveolin is 
associated with prostate and breast cancer. Clin Cancer Res 4:1873-1880. 
 145 
 
Yang F, Zhang Z, Xin D, Shi C, Wu J, Guo Y and Guan Y (2005) Peroxisome 
proliferator-activated recpetor gamma ligands induce cell cycle arrest and 
apoptosis in human renal cell carcinoma. Urology 26:753-761. 
Yang J, Haworth L, Sherry R, Hwu P, Shwartzentruber D, Topalian S, Steinberg 
S, Chen H, Rosenberg S (2003) A randomized trial of bevacizumab, an anti-
vascular endothelial growth factor antibody, for metastatic renal cancer. N 
Engl J Med 349:427-434.  
Yarden Y and Ullrich A (1988) EGF and erbB2 receptor overexpression in 
human tumors.  Growth factor receptor tyrosine kinases. Annu Rev Biochem 
57:443-478. 
Young R (1998) Metastatic renal cell carcinoma: what causes occaisional 
dramatic regressions? New Engl J Med 19:1649-1657. 
Yuan J, Castelao J, Gago-Dominguez M, Ross R, and Yu M (1998) 
Hypertension, obesity and their medications in relation to renal cell carcinoma. 
Br J Cancer 77:1508-1513.  
Yuan J, Takahashi A, Masumori N, Itoh N, Kitamura I and Tsukamoto T (2006) 
Peroxisome proliferator-activated receptor gamma is frequently 
underexpressed in renal cell carcinoma. Int J Urol 13:265-270. 
Yuan, J, Takahashi A, Masumori N, Uchida K, Hisasue S, Kitamura I and 
Tsukamoto T (2005) Ligands for Peroxisome Proliferator-activated receptor 
gamma have potent antitumor effect against human renal cell carcinoma. 
Urology 65:594-599. 
 146 
 
Zander T, Kraus J, Grommes C, Schlegel U, Feinstein D, Klockgether T, 
Landreth Gm Koenisknect J, Heneka M (2000) Induction of apoptosis in 
human and rat gliomaby agonists of nuclear receptor PPARgamma. J 
Neurosci Res 62:67-74.  
Zhang T, Heng L, Shang X, Tian Y, Zheng C, Wang S, Cheng H and Zhou R 
(2006) Nicotine prevents the apoptosis induced by menadione in human lung 
cancer cells. Biochem Piophys Res Commun 342:928-934. 
Zhang T, Wang L, Hashmi M, Anders M, Thorpe C and Ridge D (1995) Fourier-
transform ion cyclotron resonance mass spectrometric evidence for the 
formation of a α-chloroethenethiolates and thioketenes from chloroalkene-
derived cytotoxic 4-thiaalkanoates. Chem Res Toxicol 8:907-910. 
Zeng H, Dvorak H and Mukhopadyay D (2001) Vascular permeability factor 
(VPF)/ vascular endothelail growth factor (VEGF) receptor-1 down-modulates 
VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not 
migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol 
Chem 276:26969-26979.  
 147 
 
VITA 
Name:                      Melissa Dawn York 
Professional title:        Graduate Assistant Research 
Mailing Address:         2121 W. Holcombe Blvd. Rm 413 
Houston TX 77030 
 
Toxicology Program Completion:  3.0 years 
  
E-mail Address:         myork2004@gmail.com 
 
Personal Information: 
  
Education:  Present (Master of Science in Toxicology) 
Texas A&M University, College Station, TX (GPA 3.87/4.0) 
                               2000-2004 BS Biology 
Texas A&M University, College Station, TX (GPA 3.77/4.0) 
          
Internships:  2003 Research Experience for Undergraduates 
 
Awards:  2004-2006 Graduate Fellowship 
   Association of Former Students 
 
Published Articles 
York, M., Abdelrahim M, Chintharlapalli S and Safe, S. (2007) 1,1-Bis(3’-
Indolyl)-1-(ρ-substitutedphenyl)methanes induce apoptosis and inhibit renal 
cell carcinoma growth.  Submitted to Clinical Cancer Research. 
Poster and Oral Presentations:   
York, M., Abdelrahim M, Chintharlapalli S and  Safe, S. (2006) 1,1-Bis(3’-
Indolyl)-1-(ρ-substitutedphenyl)methanes induce apoptosis and inhibit renal 
cell carcinoma growth.  Student Research Week.  Texas A&M University, 
College Station, Texas. 
York, M and Safe, S. (2006) 1,1-Bis(3’-Indolyl)-1-(ρ-substitutedphenyl)methanes 
are Peroxsisome Proliferator-Activated Receptor γ Agonists that Decrease 
Clear Cell Renal Carinoma Cell Survival Through Growth Inhibition, Induction 
of ER Stress and Increased Expression of NAG-1.  Toxicology Symposium.  
College of Veterinary Medicine and Biomedical Sciences, Texas A&M 
University, College Station, Texas. 
York M, Reese E.D, Autenreith R.L. and Donnelly, K.C.  (2003)  Mutagenicity of 
PAHs in Binary Mixtures.  Texas A&M Research Symposium.  Texas A&M 
Universitiy, College Station, Texas. 
 
